var title_f20_1_20496="FDG PET CT axilla";
var content_f20_1_20496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    FDG-PET/CT of metastatic disease in an axillary lymph node",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The image demonstrates metastatic disease in an axillary lymph node as seen on an integrated 18-fluoro-2-deoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) scan. The increased activity of the lymph node is the result of the uptake and accumulation of FDG by the metabolically active tumor cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_1_20496=[""].join("\n");
var outline_f20_1_20496=null;
var title_f20_1_20497="Adson bayonet forceps";
var content_f20_1_20497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 517px\">",
"   <div class=\"ttl\">",
"    Adson bayonet forceps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 497px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Adson bayonet forceps (on right) can provide a better line of vision (as opposed to straight forceps).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_1_20497=[""].join("\n");
var outline_f20_1_20497=null;
var title_f20_1_20498="Acute paracoccoci";
var content_f20_1_20498=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Manifestations of acute paracoccidioidomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 325px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Children presenting with acute paracoccidioidomycosis. A. Abscesses on the forehead and clavicular region resulting in osteoarticular involvement. B. Girl presenting with abscess formation originating in the lymph nodes. C. Inguinal lymphadenopathy. D. Abdominal lymphadenopathy with ascites and hepatosplenomegaly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shikanai-Yasuda, MA, Queiroz Telles Filho, F, Mendes, RP, et al. Consenso em paracoccidioidomicose [Guidelines in paracoccidioidomycosis]. Revista da Sociedade Brasileira de Medicina Tropical 2006; 39:297-310. Copyright &copy;2006 Sociedade Brasileira de Medicina Tropical.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_1_20498=[""].join("\n");
var outline_f20_1_20498=null;
var title_f20_1_20499="Pelvic examination under anesthesia";
var content_f20_1_20499=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pelvic examination under anesthesia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/1/20499/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/1/20499/contributors\">",
"     William J Mann, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/1/20499/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/1/20499/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/1/20499/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/1/20499/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/1/20499/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic examination under anesthesia is performed when a patient cannot be adequately examined without sedation or general anesthesia (eg, for reasons of physical or psychological discomfort) or to provide information that will help guide a subsequent surgical procedure. In addition, clinical staging of cervical or vaginal cancer is performed under anesthesia.",
"   </p>",
"   <p>",
"    Pelvic examination under anesthesia in adults is reviewed here. General principles of the gynecologic history and physical examination in adults and children, and of cervical cancer staging, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42681?source=see_link\">",
"     \"The gynecologic history and pelvic examination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43316?source=see_link\">",
"     \"Gynecologic examination of the newborn and child\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=see_link\">",
"     \"Vaginal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INFORMED CONSENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Informed consent is required prior to performing a pelvic examination under anesthesia (EUA) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20499/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The surgeon should discuss with the patient the purpose of the EUA, as well as the personnel who will perform the examination (eg, surgeon, assisting surgeon, residents, medical students) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20499/abstract/4\">",
"     4",
"    </a>",
"    ]. This discussion should be documented on the surgical consent form and in the medical record. This applies whether the EUA is used solely or in part for the purpose of teaching medical students or trainees.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GOALS OF THE EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determination of the axis and length of the cervix and the size, position, mobility, and descent of the uterus just prior to a procedure provides the following benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confirms feasibility of vaginal route of surgery.",
"     </li>",
"     <li>",
"      Informs decision regarding vertical or transverse abdominal incision.",
"     </li>",
"     <li>",
"      Helps to avoid perforation of the uterus when intrauterine instruments are placed.",
"     </li>",
"     <li>",
"      Confirms size and location of a pelvic mass or other findings. Often due to the muscle relaxation induced by anesthesia, the EUA may reveal findings that were not appreciated during ambulatory evaluation (eg, pelvic or abdominal mass, parametrial nodularity) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20499/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gives information regarding potential adhesive disease.",
"     </li>",
"     <li>",
"      Allows examination of patients and use of examination techniques (eg, palpation of the uterosacral ligaments) that were not previously possible due to patient discomfort.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, clinical experience for surgeons, trainees, and students is enhanced by comparing the results obtained preoperatively from pelvic examination, laboratory evaluation, and imaging studies and then correlating these findings with the pathology noted during surgery.",
"   </p>",
"   <p>",
"    Some, but not all pelvic findings are not identified during an EUA. In a prospective study, for example, 84 women consented to an EUA prior to laparoscopy or laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20499/abstract/6\">",
"     6",
"    </a>",
"    ]. For an EUA performed by an attending surgeon, the sensitivity and specificity for detecting abnormalities were: adnexal mass (28 and 93 percent) and uterine enlargement (&ge;8 weeks' size; 36 and 68 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20499/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. There are no data comparing the accuracy of pelvic examination performed with and without anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;EUA prior to gynecologic surgery usually consists of examination of the abdomen and pelvis. The components of the examination will vary according to the indication for the surgery or if a routine examination is performed in a women who cannot tolerate an ambulatory examination. In women with suspected metastases from a gynecologic malignancy, additional examination may be performed.",
"   </p>",
"   <p>",
"    One limitation of the EUA is that it is not possible to assess tenderness of any structure. As with ambulatory pelvic examination, patient characteristics such as obesity, uterine size, and abdominal scars may limit the findings of EUA [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20499/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the EUA is presented below. General principles of performing a pelvic examination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42681?source=see_link&amp;anchor=H13#H13\">",
"     \"The gynecologic history and pelvic examination\", section on 'Pelvic examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination is best done after anesthesia has been administered, and prior to sterile preparation or draping of the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Abdominal examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examiner should visually inspect the abdomen. With loss of muscle tone due to anesthesia, unexpected bulges or depressions may also be observed in the abdomen or pelvis.",
"   </p>",
"   <p>",
"    Abdominal palpation is performed to exclude umbilical or incisional hernias, hepatomegaly, splenomegaly, masses, and ascites. Unsuspected hepatomegaly or splenomegaly is a concern when upper abdominal laparoscopy ports are planned; occasionally, an enlarged liver may extend to the level of the umbilical port. A broad mass just deep to the abdominal wall may represent an omental cake; this",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fixation of the umbilicus are potential signs of advanced intraperitoneal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12168?source=see_link\">",
"     \"Gynecologic laparoscopy: Non-umbilical entry sites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pelvic examination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Vulva and surrounding structures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin of the vulva is inspected and palpated. Palpable vulvar lesions may be lifted to assess depth of involvement, and mobility. In particular, areas which were tender due to ulceration or inflammation can be palpated and visualized by stretching the skin taught across the vulva. Lesions can also be moved relative to the urethra or anus, to assess whether these orifices have been involved by an inflammatory or malignant process. Enlarged nodes may be seen in the inguinal areas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Speculum examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual examination of the vagina and cervix is performed in women with suspected vaginal or cervical lesions or pelvic organ prolapse. This examination can be performed using a speculum or retractors. The vaginal speculum can typically be opened more widely than when the patient is awake, allowing the fornices to be thoroughly inspected. The cervix can also be moved to aid in visualizing upper vaginal lesions. Any abnormalities of the vagina or cervix should be examined with a bright light or colposcope. Biopsy may be indicated.",
"   </p>",
"   <p>",
"    For women who cannot tolerate an ambulatory pelvic examination, anesthesia allows the only opportunity to visualize the vagina and cervix and obtain cytology and cultures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bimanual examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bimanual examination is performed in the same manner as for other pelvic examinations. The vagina and cervix are assessed for palpable lesions, and the cervix and uterus are assessed for axis, size, position, mobility, and descent. The adnexae are palpated. I conclude the EUA by performing a rectovaginal examination.",
"   </p>",
"   <p>",
"    Palpable abnormalities on bimanual examination are assessed for consistency, mobility, and relation to adjacent structures (ie, anterior or posterior to the uterus or vagina, attached or separate from the uterus, fixed to the side wall or mobile).",
"   </p>",
"   <p>",
"    Findings of a large or fixed pelvic mass may lead the surgeon to choose an abdominal rather than a vaginal surgical route.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Assessment for metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with potential metastatic disease, an examination of lymph nodes and a breast examination may be performed. The examiner should note whether nodes are enlarged, and assess for resectability or fixation. Biopsy or aspiration may be appropriate.",
"   </p>",
"   <p>",
"    A breast examination may be performed, if appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link&amp;anchor=H14#H14\">",
"     \"Breast masses and other common breast problems\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pelvic examination under anesthesia (EUA) is performed when a patient cannot be adequately examined without sedation or general anesthesia (eg, for reasons of physical or psychological discomfort) or to provide information that will help guide a subsequent surgical procedure. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical staging of cervical or vaginal cancer is performed under anesthesia. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Informed consent is required prior to performing an EUA. The surgeon should discuss with the patient the purpose of the EUA, as well as the personnel who will perform the examination. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Informed consent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EUA prior to gynecologic surgery usually consists of examination of the abdomen and pelvis. In women with suspected metastases from a gynecologic malignancy, additional examination may be performed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20499/abstract/1\">",
"      ACOG Committee on Ethics. ACOG Committee Opinion No. 358: professional responsibilities in obstetric-gynecologic education. Obstet Gynecol 2007; 109:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20499/abstract/2\">",
"      Wainberg S, Wrigley H, Fair J, Ross S. Teaching pelvic examinations under anaesthesia: what do women think? J Obstet Gynaecol Can 2010; 32:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20499/abstract/3\">",
"      York-Best CM, Ecker JL. Pelvic examinations under anesthesia: a teachable moment. Obstet Gynecol 2012; 120:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20499/abstract/4\">",
"      Wilson RF. Unauthorized practice: teaching pelvic examination on women under anesthesia. J Am Med Womens Assoc 2003; 58:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20499/abstract/5\">",
"      Ozaksit G, Caglar T, Zorlu CG, et al. Chronic pelvic pain in adolescent women. Diagnostic laparoscopy and ultrasonography. J Reprod Med 1995; 40:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20499/abstract/6\">",
"      Padilla LA, Radosevich DM, Milad MP. Limitations of the pelvic examination for evaluation of the female pelvic organs. Int J Gynaecol Obstet 2005; 88:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20499/abstract/7\">",
"      Padilla LA, Radosevich DM, Milad MP. Accuracy of the pelvic examination in detecting adnexal masses. Obstet Gynecol 2000; 96:593.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3256 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-190.81.197.98-74C7246191-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_1_20499=[""].join("\n");
var outline_f20_1_20499=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INFORMED CONSENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GOALS OF THE EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Abdominal examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pelvic examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Vulva and surrounding structures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Speculum examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bimanual examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Assessment for metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=related_link\">",
"      Breast masses and other common breast problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43316?source=related_link\">",
"      Gynecologic examination of the newborn and child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12168?source=related_link\">",
"      Gynecologic laparoscopy: Non-umbilical entry sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=related_link\">",
"      Invasive cervical cancer: Staging and evaluation of lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42681?source=related_link\">",
"      The gynecologic history and pelvic examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31208?source=related_link\">",
"      Vaginal cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_1_20500="Bedbugs PI";
var content_f20_1_20500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F66540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F66540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Bedbugs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bedbugs are reddish brown and similar in size to a dog tick. They have flat, oval bodies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dirk M Elston, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_1_20500=[""].join("\n");
var outline_f20_1_20500=null;
var title_f20_1_20501="Boceprevir: Patient drug information";
var content_f20_1_20501=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Boceprevir: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     see \"Boceprevir: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12838380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Victrelis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13203002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Victrelis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12851864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F12851887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691882",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hepatitis C infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12851858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3449028",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to boceprevir or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3449030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are",
"       <b>",
"        not",
"       </b>",
"       taking ribavirin or peginterferon alfa.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701069",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are of childbearing age, but are not using 2 kinds of birth control or if you are planning to get pregnant during your care or within 6 months after care has ended.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with a sex partner who is pregnant or plans on getting pregnant at any time while you are being treated or within 6 months after your care has ended.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F12851860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697168",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have anemia, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697273",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have HIV infection, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697234",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an organ transplant, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having surgery, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use 2 kinds of birth control that you can trust while using this drug and for 6 months after stopping this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697016",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy during care and for 6 months after care ends. Use birth control that you can trust.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696918",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use a hormone-related kind of birth control.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F12851890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697868",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia and low white blood cell count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698628",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698113",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12851862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F12851889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F12851859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F12851893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store capsules in a refrigerator.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3449032",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may also store this drug at room temperature. Throw away any part not used after 3 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F12851863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16493 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_1_20501=[""].join("\n");
var outline_f20_1_20501=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12838380\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203002\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851864\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851887\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851858\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851860\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851890\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851862\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851889\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851859\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851893\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12851863\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=related_link\">",
"      Boceprevir: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_1_20502="Ileal J pouch construction and identification of the apex";
var content_f20_1_20502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Ileal J pouch construction and identification of the apex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows the construction of the J-pouch. A suture is used to mark the apex of the loop of ileum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_1_20502=[""].join("\n");
var outline_f20_1_20502=null;
var title_f20_1_20503="ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation";
var content_f20_1_20503=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/1/20503/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/1/20503/contributors\">",
"     E Kevin Heist, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/1/20503/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/1/20503/contributors\">",
"     Samuel L&eacute;vy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/1/20503/contributors\">",
"     Hugh Calkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/1/20503/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/1/20503/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/1/20503/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies suggested that angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and (possibly) aldosterone antagonists might either prevent new onset and recurrent atrial fibrillation (AF) or reduce the rate of major adverse cardiovascular outcomes in these patients. However, the available data do not support the use of these drugs solely for these purposes.",
"   </p>",
"   <p>",
"    In this topic ACE inhibitors and ARBs collectively will be referred to as &lsquo;angiotensin inhibition.&rsquo;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     POSSIBLE MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanisms proposed to explain the benefit of angiotensin blockade found in the early studies included the direct effects of angiotensin blockade on the structural and electrical properties of the atria, as well as the indirect influence of improved control of heart failure and hypertension, both of which are known risk factors for AF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=see_link\">",
"     \"The electrocardiogram in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=see_link\">",
"     \"Actions of angiotensin II on the heart\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations supported the proposed mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduction in atrial stretch &mdash; Atrial stretch, due to increased left atrial (LA) pressure, is associated with changes in the refractory period and conduction properties of atrial myocardium. These abnormalities provide both potential triggers and the substrate for the initiation and perpetuation of AF. The hemodynamic effects of ACE inhibitors and ARBs result in improved ventricular function and also reductions in LA pressure and wall stress [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prevention of atrial fibrosis &mdash; Fibrosis in the atrial myocardium may be an important component of the substrate necessary for AF. Atrial fibrosis is stimulated by elevated levels of angiotensin-II [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/3\">",
"       3",
"      </a>",
"      ] and reduced by treatment with ACE inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prevention of electrical remodeling and direct antiarrhythmic effects &mdash; Direct effects of angiotensin blockade on ion channels and electrophysiologic properties have been suggested [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/6\">",
"       6",
"      </a>",
"      ], but data from both animal and human studies have been conflicting and inconclusive. Recent canine work has suggested direct inhibition of triggering of atrial arrhythmias by ACE inhibitors and ARBs [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVENTION OF NEW ONSET AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Post hoc analyses of randomized trials and observations from nonrandomized studies have suggested that ACE inhibitors and ARBs reduce the incidence of new AF in a variety of settings including the treatment of left ventricular dysfunction or hypertension, and after coronary artery bypass graft surgery (CABG).",
"   </p>",
"   <p>",
"    The following findings were noted in a 2010 meta-analysis of data from 26 randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ACE inhibitors and ARBs significantly reduced the risk of the development of AF (Odds Ratio [OR] 0.65, 95% CI 0.55-0.76); the benefit was equivalent with the two classes of drugs.",
"     </li>",
"     <li>",
"      The benefit of ACE inhibitors and ARBs appeared large in patients with systolic heart failure (OR 0.50), but the result was not statistically significant (95% CI 0.19-1.16).",
"     </li>",
"     <li>",
"      The effect of ACE inhibitors and ARBs was greater in preventing recurrent AF (OR 0.45, 95% CI 0.31-0.65) compared to new-onset AF (OR 0.80, 95% CI 0.70-0.92)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the strength of the conclusions from the meta-analysis is weakened due the inclusion of post hoc analyses of randomized trials performed for reasons other than prevention of AF (eg, heart failure, post-MI, or hypertension), heterogeneity, and the likely presence of publication or ascertainment bias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Left ventricular dysfunction or heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the TRACE trial of patients with left ventricular dysfunction and sinus rhythm after an acute myocardial infarction,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/41/12952?source=see_link\">",
"     trandolapril",
"    </a>",
"    therapy was associated with a significantly reduced incidence of subsequent AF at two- to four-year follow-up (2.8 versus 5.3 percent with placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings were noted in retrospective analyses from the randomized trials SOLVD and Val-HeFT, which enrolled patients with chronic left ventricular dysfunction, almost all of whom had ischemic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In the SOLVD trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    significantly reduced the incidence of subsequent AF at a mean follow-up of 2.9 years (5.4 versus 24 percent with placebo, hazard ratio 0.22). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A smaller reduction in the incidence of new AF with the ARB",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    was noted in the CHARM trials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/12\">",
"     12",
"    </a>",
"    ]. Among 7601 patients enrolled in the three trials, 6379 patients did not have AF at baseline. At a median follow-up of 38 months, candesartan produced a significant reduction in the incidence of new AF of borderline statistical significance (5.6 versus 6.7 percent).",
"   </p>",
"   <p>",
"    The CHARM trials enrolled patients with both systolic and diastolic dysfunction as well as symptomatic heart failure, and used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    both as an alternative to and in conjunction with an ACE inhibitor. Thus, the reason that candesartan had a less substantial effect on the incidence of AF than was seen in earlier trials of ACE inhibitors is unclear. Possible explanations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An intrinsic effect of the drug or drug class.",
"     </li>",
"     <li>",
"      The beneficial effect may be less prominent in patients with diastolic dysfunction, thus diluting the overall effect.",
"     </li>",
"     <li>",
"      The beneficial effect may already have been achieved in the patients who were already taking an ACE inhibitor, which could also dilute the overall effect of the ARB.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/13-17\">",
"     13-17",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/18-20\">",
"     18-20",
"    </a>",
"    ], studies comparing ACE inhibitors or ARBs to other classes of drugs in patients with hypertension have shown a lowering of the risk of development AF. A 2010 meta-analysis of trials with substantial heterogeneity found no significant reduction in the risk for AF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Societal guidelines and our recommendations for the use of angiotensin inhibition to prevent AF are found below. (See",
"    <a class=\"local\" href=\"#H986438\">",
"     'Recommendations of others'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11\">",
"     'Summary and recommendations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The role of angiotensin blockade in the treatment of hypertension is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H28#H28\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H621977831\">",
"    <span class=\"h2\">",
"     Patients with other risk factors for AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of whether these therapies might prevent the development of AF in patients with risk factors other than left ventricular dysfunction, heart failure, or hypertension, such as diabetes or coronary artery disease, has not been well studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Coronary artery bypass graft",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a prospective study of 4657 patients undergoing CABG, postoperative AF occurred significantly less often in patients who were treated preoperatively and postoperatively with ACE inhibitors compared to those who were not (20 versus 34 percent, odds ratio 0.62) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, patients who had previously been taking ACE inhibitors and were withdrawn from therapy had a significant increase in risk (46 percent, odds ratio 1.69). The utility of these agents in preventing AF after cardiac surgery remains controversial, however, as other studies have not found a significant benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTION OF RECURRENT AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;In small trials that enrolled fewer than 200 patients, ACE inhibitors or ARBs in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    reduced the rate of recurrent AF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. However, these results were not confirmed in the GISSI-AF trial, which randomly assigned 1442 patients with a history of symptomatic AF and in sinus rhythm to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/31\">",
"     31",
"    </a>",
"    ]. All patients had underlying cardiovascular disease, diabetes, or left atrial enlargement.",
"   </p>",
"   <p>",
"    GISSI-AF found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/4/31815?source=see_link\">",
"     valsartan",
"    </a>",
"    did NOT prevent recurrent AF. At one-year follow-up, there was no significant difference between valsartan or placebo in the proportion of patients who had more than one episode of AF (51 versus 52 percent, adjusted hazard ratio 0.97, 95% CI 0.83-1.14) or in the median time from randomization to the first recurrence of AF (295 versus 291 days). Although 57 percent of patients were taking an ACE inhibitor and 70 percent were taking antiarrhythmic drugs at baseline that were continued throughout the trial and might have confounded the results, the outcomes in subgroup analysis were similar in the patients who were or were not being treated with such agents.",
"   </p>",
"   <p>",
"    Another possible contributor to the lack of benefit in GISSI-AF was a low prevalence of heart",
"    <span class=\"nowrap\">",
"     failure/left",
"    </span>",
"    ventricular dysfunction (8 percent), since the meta-analysis cited above found that the benefit was greatest in patients with these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention of recurrent AF with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=see_link\">",
"     irbesartan",
"    </a>",
"    was also analyzed in the ACTIVE I study, which randomized 9016 patients with a history of AF, stroke risk factors and a systolic blood pressure of at least 110 mm Hg to either irbesartan 300 mg once daily or placebo. Patients who received irbesartan in ACTIVE I were not significantly more likely to be in sinus rhythm at subsequent follow-up, regardless of whether they were initially in AF at baseline or in sinus rhythm at baseline (RR 0.97, p = 0.61).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H615512240\">",
"    <span class=\"h2\">",
"     Aldosterone inhibition and AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are data from animal and human studies to suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    , an aldosterone antagonist, may reduce recurrent AF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. We do not recommend aldosterone inhibition for this purpose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H615512079\">",
"    <span class=\"h2\">",
"     Catheter ablation of AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data are mixed as to whether ACE",
"    <span class=\"nowrap\">",
"     inhibitors/ARBs",
"    </span>",
"    reduce AF after radiofrequency catheter ablation procedures: A significant benefit was seen in some [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/35\">",
"     35",
"    </a>",
"    ], but not other [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/36,37\">",
"     36,37",
"    </a>",
"    ] studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110572908\">",
"    <span class=\"h1\">",
"     PREVENTION OF CARDIOVASCULAR EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed in the sections on prevention above, the benefit of either ACE inhibitor or ARB therapy for the prevention of new or recurrent AF is uncertain. The issue of whether ARB therapy can reduce the rate of major adverse cardiovascular events in patients with AF was addressed in the ACTIVE I trial, which enrolled individuals with either permanent AF or at least two episodes of intermittent AF (in the previous six months) from the ACTIVE A and ACTIVE W trials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H19#H19\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Aspirin plus clopidogrel'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Prevention of recurrent AF'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Mean reductions in systolic and diastolic blood pressures were 2.9 and 1.9 mmHg greater in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/37/21079?source=see_link\">",
"     irbesartan",
"    </a>",
"    group. At a mean follow-up of 4.1 years, the following findings were noted in the irbesartan and placebo groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference in the rates of the first combined co-primary outcome of stroke, myocardial infarction, or death from vascular causes (5.4 percent per 100 person-years in both groups).",
"     </li>",
"     <li>",
"      There was no significant difference in the rates of the second combined co-primary outcome, which included the components of the first co-primary outcome plus the rate of hospitalization for heart failure (7.3 and 7.7 percent per 100 person-years in the two groups, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential benefit from the use of ACE inhibitor and ARB therapy in patients with cardiovascular disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link\">",
"     \"Blood pressure management in patients with atherosclerotic cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H986438\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology guidelines for the management of patients with AF stated that the role of angiotensin inhibition for the prevention of AF needed further clarification before a recommendation for their use could be made [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/39\">",
"     39",
"    </a>",
"    ]. This issue was not addressed in the 2011",
"    <span class=\"nowrap\">",
"     ACCF/AHA/Heart",
"    </span>",
"    Rhythm Society focused update [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20503/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2010 European Society of Cardiology (ESC) guidelines for the management of AF made the following recommendations for the use of angiotensin inhibition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For primary prevention of AF:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Weak recommendations were made for the prevention new onset AF in patients with heart failure and a reduced ejection fraction as well as for those with hypertension, particularly with left ventricular hypertrophy.",
"     </li>",
"     <li>",
"      Upstream angiotensin inhibition was not recommended for the prevention of AF in patients without cardiovascular disease; no recommendation was made for those with cardiovascular disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For secondary prevention of AF, pretreatment with angiotensin inhibition may be considered in patients with recurrent AF and receiving antiarrhythmic drug therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our experts do not believe the evidence is strong enough to support the recommendations made by the ESC for either the primary prevention of new onset AF in patients with hypertension, or for the secondary prevention in patients with recurrent AF receiving antiarrhythmic drug therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who require treatment for cardiovascular conditions other than atrial fibrillation (AF) such as hypertension or heart failure, it may be reasonable to select an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) as treatment for that condition, with the possibility that it might also reduce new or recurrent AF.",
"   </p>",
"   <p>",
"    There is a plausible scientific basis for the notion that inhibition of the renin-angiotensin-aldosterone system can reduce the incidence of AF. Possible mechanisms include reducing atrial stretch, limiting atrial fibrosis, inhibiting triggering from the pulmonary veins, and preventing atrial remodeling. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Possible mechanisms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Secondary analyses of randomized trials performed for reasons other than AF prevention suggest that ACE inhibitors and ARBs reduce the incidence of new onset AF. However, publication bias and heterogeneity of the trials renders the evidence to support their use weak. The greatest benefit was seen in patients with heart",
"    <span class=\"nowrap\">",
"     failure/left",
"    </span>",
"    ventricular dysfunction in whom therapy with an ACE inhibitor or ARB is probably already indicated. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Prevention of new onset AF'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with a cardiovascular condition, such as heart failure or hypertension, in which the use of an ACE inhibitor or an ARB might be either indicated or reasonable, it is possible that their use might reduce the likelihood of new or recurrent AF. However, we do not recommend angiotensin inhibition in preference to other therapy solely for the prevention of atrial fibrillation. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Prevention of recurrent AF'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Our recommendations for the use of angiotensin blockade to prevent AF are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients at risk for AF but without an indication for angiotensin blockade, we recommend NOT initiating therapy with an ACE inhibitor or ARB solely to prevent new onset AF (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevention of new onset AF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with a history of AF, we recommend NOT treating with an ACE inhibitor or ARB for the sole purpose of preventing recurrent AF (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prevention of recurrent AF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not recommend use of an angiotensin receptor blocker for the prevention of cardiovascular events in patients with AF whose blood pressure is at or below goal. (See",
"      <a class=\"local\" href=\"#H110572908\">",
"       'Prevention of cardiovascular events'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=see_link&amp;anchor=H19#H19\">",
"       \"Blood pressure management in patients with atherosclerotic cardiovascular disease\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/1\">",
"      Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006; 27:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/2\">",
"      Webster MW, Fitzpatrick MA, Nicholls MG, et al. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 1985; 56:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/3\">",
"      McEwan PE, Gray GA, Sherry L, et al. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998; 98:2765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/4\">",
"      Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104:2608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/5\">",
"      Sakabe M, Fujiki A, Nishida K, et al. Enalapril prevents perpetuation of atrial fibrillation by suppressing atrial fibrosis and over-expression of connexin43 in a canine model of atrial pacing-induced left ventricular dysfunction. J Cardiovasc Pharmacol 2004; 43:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/6\">",
"      Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101:2612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/7\">",
"      Sicouri S, Cordeiro JM, Talarico M, Antzelevitch C. Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol 2011; 22:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/8\">",
"      Zhang Y, Zhang P, Mu Y, et al. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Clin Pharmacol Ther 2010; 88:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/9\">",
"      Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/10\">",
"      Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107:2926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/11\">",
"      Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/12\">",
"      Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/13\">",
"      Schaer BA, Schneider C, Jick SS, et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med 2010; 152:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/14\">",
"      L'Allier PL, Ducharme A, Keller PF, et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004; 44:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/15\">",
"      Dahl&ouml;f B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/16\">",
"      Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/17\">",
"      Heckbert SR, Wiggins KL, Glazer NL, et al. Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. Am J Hypertens 2009; 22:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/18\">",
"      Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/19\">",
"      Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/20\">",
"      Yamashita T, Inoue H, Okumura K, et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011; 13:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/21\">",
"      Schneider MP, Hua TA, B&ouml;hm M, et al. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010; 55:2299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/22\">",
"      Mathew JP, Fontes ML, Tudor IC, et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004; 291:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/23\">",
"      Shariff N, Zelenkofske S, Eid S, et al. Demographic determinants and effect of pre-operative angiotensin converting enzyme inhibitors and angiotensin receptor blockers on the occurrence of atrial fibrillation after CABG surgery. BMC Cardiovasc Disord 2010; 10:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/24\">",
"      Coleman CI, Makanji S, Kluger J, White CM. Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation. Ann Pharmacother 2007; 41:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/25\">",
"      White CM, Kluger J, Lertsburapa K, et al. Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III. Eur J Cardiothorac Surg 2007; 31:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/26\">",
"      Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/27\">",
"      Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/28\">",
"      Yin Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006; 27:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/29\">",
"      Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006; 47:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/30\">",
"      Belluzzi F, Sernesi L, Preti P, et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009; 53:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/31\">",
"      GISSI-AF Investigators, Disertori M, Latini R, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/32\">",
"      Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/33\">",
"      Zhao J, Li J, Li W, et al. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol 2010; 159:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/34\">",
"      Dabrowski R, Borowiec A, Smolis-Bak E, et al. Effect of combined spironolactone-&beta;-blocker &plusmn; enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). Am J Cardiol 2010; 106:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/35\">",
"      Klemm HU, Heitzer T, Ruprecht U, et al. Impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the long-term outcome after pulmonary vein isolation for paroxysmal atrial fibrillation. Cardiology 2010; 117:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/36\">",
"      Richter B, Derntl M, Marx M, et al. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation. Am Heart J 2007; 153:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/37\">",
"      Al Chekakie MO, Akar JG, Wang F, et al. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol 2007; 18:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/38\">",
"      ACTIVE I Investigators, Yusuf S, Healey JS, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011; 364:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/39\">",
"      Fuster V, Ryd&eacute;n LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20503/abstract/40\">",
"      Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123:104.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 935 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-49D3304717-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_1_20503=[""].join("\n");
var outline_f20_1_20503=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      POSSIBLE MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVENTION OF NEW ONSET AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Left ventricular dysfunction or heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H621977831\">",
"      Patients with other risk factors for AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Coronary artery bypass graft",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTION OF RECURRENT AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H615512240\">",
"      Aldosterone inhibition and AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H615512079\">",
"      Catheter ablation of AF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110572908\">",
"      PREVENTION OF CARDIOVASCULAR EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H986438\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26088?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29737?source=related_link\">",
"      Blood pressure management in patients with atherosclerotic cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_1_20504="Acetylcysteine: Drug information";
var content_f20_1_20504=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetylcysteine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?7/12/7365?source=see_link\">",
"    see \"Acetylcysteine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"    see \"Acetylcysteine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acetadote&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F130168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acetylcysteine Injection;",
"     </li>",
"     <li>",
"      Acetylcysteine Solution;",
"     </li>",
"     <li>",
"      Mucomyst&reg;;",
"     </li>",
"     <li>",
"      Parvolex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F130213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Mucolytic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F130171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acetaminophen poisoning:",
"     </b>",
"     Only the 72-hour oral and 21-hour I.V. regimens are FDA-approved.  Ideally, in patients with an acute acetaminophen ingestion, treatment should begin within 8 hours of ingestion or as soon as possible after ingestion. In patients who present following RSTI and treatment is deemed appropriate, acetylcysteine should be initiated immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Consultation with a poison control center or clinical toxicologist is highly recommended when considering the discontinuation of oral acetylcysteine prior to the conclusion of a full 18-dose course of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     72-hour regimen: Consists of 18 doses; total dose delivered: 1330 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Loading dose: 140 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maintenance dose: 70 mg/kg every 4 hours; repeat dose if emesis occurs within 1 hour of administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      I.V.",
"     </i>",
"     (Acetadote&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     21-hour regimen: Consists of 3 doses; total dose delivered: 300 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Loading dose: 150 mg/kg (maximum: 15 g) infused over 60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Second dose: 50 mg/kg (maximum: 5 g) infused over 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Third dose: 100 mg/kg (maximum: 10 g) infused over 16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The fluid volume should be reduced in patients weighing &lt;40 kg according to the following table:",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Acetadote&reg; Dosing / Fluid Volume Guidelines for Patients &lt;40 kg",
"     </caption>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"75\">",
"     </col>",
"     <col align=\"center\" width=\"75\">",
"     </col>",
"     <col align=\"center\" width=\"75\">",
"     </col>",
"     <col align=\"center\" width=\"75\">",
"     </col>",
"     <col align=\"center\" width=\"75\">",
"     </col>",
"     <col align=\"center\" width=\"75\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Body Weight",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (kg)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Loading Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         150 mg/kg over 1 h",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Second Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         50 mg/kg over 4 h",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Third Dose",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         100 mg/kg over 16 h",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Acetadote&reg;",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mL)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         D",
"         <sub>",
"          5",
"         </sub>",
"         W",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mL)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Acetadote&reg;",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mL)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         D",
"         <sub>",
"          5",
"         </sub>",
"         W",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mL)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Acetadote&reg;",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mL)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         D",
"         <sub>",
"          5",
"         </sub>",
"         W",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mL)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         22.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         18.75",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6.25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         500",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         140",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         280",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11.25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         45",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.75",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         105",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         210",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         70",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         140",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Adjuvant therapy in respiratory conditions:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients should receive an aerosolized bronchodilator 10-15 minutes prior to dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inhalation, nebulization (face mask, mouth piece, tracheostomy):",
"     </i>",
"     Acetylcysteine 10% and 20% solution (dilute 20% solution with sodium chloride or sterile water for inhalation); 10% solution may be used undiluted: 3-5 mL of 20% solution or 6-10 mL of 10% solution until nebulized given 3-4 times/day; dosing range: 1-10 mL of 20% solution or 2-20 mL of 10% solution every 2-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inhalation, nebulization (tent, croupette):",
"     </i>",
"     Dose must be individualized; may require up to 300 mL solution/treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Direct instillation:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Into tracheostomy: 1-2 mL of 10% to 20% solution every 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Through percutaneous intratracheal catheter: 1-2 mL of 20% or 2-4 mL of 10% solution every 1-4 hours via syringe attached to catheter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Diagnostic bronchogram:",
"     </b>",
"     Nebulization or intratracheal: 1-2 mL of 20% solution or 2-4 mL of 10% solution administered 2-3 times prior to procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Prevention of contrast-induced nephropathy (CIN) (unlabeled use):",
"     </b>",
"     Oral: 600-1200 mg twice daily for 2 days (beginning the day before the procedure); may be given as powder in capsules (some centers use solution, diluted in cola beverage or juice).",
"     <b>",
"      Note:",
"     </b>",
"     No longer recommended for use prior to percutaneous coronary intervention; instead adequate hydration is preferred (Levine, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F130194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"      see \"Acetylcysteine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acetaminophen poisoning:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adjuvant therapy in respiratory conditions:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients should receive an aerosolized bronchodilator 10-15 minutes prior to acetylcysteine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inhalation, nebulization (face mask, mouth piece, tracheostomy):",
"     </i>",
"     Acetylcysteine 10% and 20% solution (dilute 20% solution with sodium chloride or sterile water for inhalation); 10% solution may be used undiluted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants: 1-2 mL of 20% solution or 2-4 mL 10% solution until nebulized given 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Inhalation, nebulization (tent, croupette):",
"     </i>",
"     Children: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F130172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15671280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral, I.V.: No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: No dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F130142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 20% (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acetadote&reg;: 20% [200 mg/mL] (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for inhalation/oral: 10% [100 mg/mL] (10 mL, 30 mL); 20% [200 mg/mL] (10 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for inhalation/oral [preservative free]: 10% [100 mg/mL] (4 mL, 10 mL); 20% [200 mg/mL] (4 mL, 10 mL, 30 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F130127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F130146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation: Acetylcysteine is incompatible with tetracyclines, erythromycin, amphotericin B, iodized oil, chymotrypsin, trypsin, and hydrogen peroxide. Administer separately. Intermittent aerosol treatments are commonly given when patient arises, before meals, and just before retiring at bedtime.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Treatment of acetaminophen poisoning, administer orally as a 5% solution. Use within 1 hour of preparation. The unpleasant odor  (sulfur-like) becomes less noticeable as treatment progresses. If patient vomits within 1 hour of dose, readminister. (",
"     <b>",
"      Note:",
"     </b>",
"     It is helpful to put the acetylcysteine on ice, in a cup with a cover, and drink through a straw; alternatively, administer via an NG tube).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. (Acetadote&reg;): Acetaminophen poisoning:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Loading dose: Administer over 60 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Second dose: Administer over 4 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Third dose: Administer over 16 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     If the commercial I.V. form is unavailable, the solution for inhalation has been used; each dose should be infused through a 0.2 micron Millipore filter (in-line) over 60 minutes (Yip, 1998); intravenous administration of the solution for inhalation is not USP 797-compliant.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F130220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation:",
"     <b>",
"      Incompatible",
"     </b>",
"     with rubber and metals (particularly iron, copper, and nickel); do not mix with ampicillin, oxytetracycline, erythromycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intravenous: Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Incompatible",
"     </b>",
"     with metals (particularly iron, copper, and nickel);  cefepime, ceftazidime",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F130145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antidote for acute acetaminophen poisoning; repeated supratherapeutic ingestion (RSTI) of acetaminophen; adjunctive mucolytic therapy in patients with abnormal or viscid mucous secretions in acute and chronic bronchopulmonary diseases; pulmonary complications of surgery and cystic fibrosis; diagnostic bronchial studies",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F130210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of contrast-induced renal dysfunction (oral, I.V.); distal intestinal obstruction syndrome (DIOS, previously referred to as meconium ileus equivalent)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F130222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acetylcysteine may be confused with acetylcholine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mucomyst&reg; may be confused with Mucinex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F130211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inhalation:",
"     </b>",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Drowsiness, chills, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting, nausea, stomatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Irritation, stickiness on face following nebulization",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchospasm, rhinorrhea, hemoptysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Acquired sensitization (rare), clamminess, unpleasant odor during administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intravenous:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Miscellaneous: Anaphylactoid reaction (8% to 18%; shorter infusion periods [eg, &lt;60 minutes] associated with increased incidence)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Flushing (1% to 8%), tachycardia (1% to 4%), edema (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Urticaria (6% to 8%), rash (2% to 4%), pruritus (1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (2% to 10%), nausea (1% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (&le;1%), rhinorrhea (&le;1%), rhonchi (&le;1%), throat tightness (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, angioedema, bronchospasm, chest tightness, cough, dizziness, dyspnea, headache, hypotension, respiratory distress, stridor, wheezing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F130149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acetylcysteine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F130131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Acute flushing and erythema have been reported; usually occurs within 30-60 minutes and may resolve spontaneously. Serious anaphylactoid reactions have also been reported and are more commonly associated with I.V. administration, but also occur with oral administration (Mroz, 1997). When used for acetaminophen poisoning, the incidence is reduced when the initial intravenous loading dose is administered over 60 minutes. The acetylcysteine infusion may be interrupted until the treatment of allergic symptoms is initiated; the infusion can then be carefully restarted. Treatment for anaphylactoid reactions should be immediately available. Use caution in patients with asthma or history of bronchospasm as these patients may be at increased risk. Conversely, patients with high acetaminophen levels (&gt;150 mg/dL) may be at a reduced risk for anaphylactoid reactions (Pakravan, 2008; Sandilands, 2009; Waring, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute acetaminophen poisoning: Appropriate use: Acetylcysteine is indicated in patients with a serum acetaminophen level that indicates they are at \"possible\" risk or greater for hepatotoxicity when plotted on the Rumack-Matthew nomogram. There are several situations where the nomogram is of limited use. Serum acetaminophen levels obtained &lt;4 hours postingestion are not interpretable; patients presenting late may have undetectable serum concentrations, despite having received a toxic dose. The nomogram is less predictive of hepatic injury following an acute overdose with an extended release acetaminophen product. The nomogram also does not take into account patients who may be at higher risk of acetaminophen toxicity (eg, alcoholics, malnourished patients).  Nevertheless, acetylcysteine should be administered to any patient with signs of hepatotoxicity, even if the serum acetaminophen level is low or undetectable. Patients who present &gt;24 hours after an acute ingestion or patients who present following an acute ingestion at an unknown time may be candidates for acetylcysteine therapy; consultation with a poison control center or clinical toxicologist is highly recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Repeated supratherapeutic ingestion (RSTI) of acetaminophen: Appropriate use: The Rumack-Matthew nomogram is not designed to be used following RSTIs. In general, an accurate past medical history, including a comprehensive acetaminophen ingestion history, in conjunction with AST concentrations and serum acetaminophen levels, may give the clinician insight as to the patient's risk of acetaminophen toxicity. Some experts recommend that acetylcysteine be administered to any patient with \"higher than expected\" serum acetaminophen levels or serum acetaminophen level &gt;10 mcg/mL, even in the absence of hepatic injury; others recommend treatment for patients with laboratory evidence and/or signs and symptoms of hepatotoxicity (Hendrickson, 2006; Jones, 2000). Consultation with a poison control center or a clinical toxicologist is highly recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhalation: Since increased bronchial secretions may develop after inhalation, percussion, postural drainage, and suctioning should follow. If bronchospasm occurs, administer a bronchodilator; discontinue acetylcysteine if bronchospasm progresses.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F130136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F130138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F130152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on limited reports using acetylcysteine to treat acetaminophen poisoning in pregnant women, acetylcysteine has been shown to cross the placenta and may provide protective levels in the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F130177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F130151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Acetadote Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/mL (30 mL): $207.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Acetylcysteine Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (10 mL): $6.52",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (30 mL): $11.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Acetylcysteine Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/mL (30 mL): $225.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F130140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acetaminophen poisoning: Monitor patient for the development of anaphylaxis or anaphylactoid reactions; monitor serum acetaminophen levels, AST, ALT, bilirubin, PT, INR, serum creatinine, BUN, serum glucose, hemoglobin, hematocrit, and electrolytes. Assess patient for nausea, vomiting, and skin rash following oral administration. Reassess LFTs for possible hepatotoxicity every 4-6 hours. An early elevation in the INR may be related to acetylcysteine therapy (Schmidt, 2002).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acute ingestion: Obtain the first acetaminophen level 4 hours postingestion (or as soon as possible thereafter); plot on the Rumack-Matthew nomogram. In patients who have ingested an extended release formulation of acetaminophen or have coingested an agent known to delay gastric emptying, obtain a repeat serum acetaminophen measurement 4-6 hours following the first measurement if the original level (taken at 4-8 hours postingestion) when plotted on the Rumack-Matthew nomogram indicated that treatment was not necessary.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F130153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      ACC (AR, HU, LU, MX, RU, ZA);",
"     </li>",
"     <li>",
"      ACC 200 (EE);",
"     </li>",
"     <li>",
"      Acemuk (AR);",
"     </li>",
"     <li>",
"      Acetadote (AU, NZ);",
"     </li>",
"     <li>",
"      Acetain (KP);",
"     </li>",
"     <li>",
"      Acetin (MY);",
"     </li>",
"     <li>",
"      Acetylcystein NM Pharma (SE);",
"     </li>",
"     <li>",
"      Acetylcystein Tika (SE);",
"     </li>",
"     <li>",
"      Acypront (HK);",
"     </li>",
"     <li>",
"      Aerosolv (AT);",
"     </li>",
"     <li>",
"      Aflux (CO);",
"     </li>",
"     <li>",
"      Brimodin (PE);",
"     </li>",
"     <li>",
"      Bromuc (BR);",
"     </li>",
"     <li>",
"      Broncoflem (PH);",
"     </li>",
"     <li>",
"      Cetilan (PH);",
"     </li>",
"     <li>",
"      Codotussyl (SG);",
"     </li>",
"     <li>",
"      Cystaline (TH);",
"     </li>",
"     <li>",
"      Ecomucyl (CH);",
"     </li>",
"     <li>",
"      Eloamin (CZ);",
"     </li>",
"     <li>",
"      Exomuc (FR, HK, LU);",
"     </li>",
"     <li>",
"      Fabrol (AT, GR);",
"     </li>",
"     <li>",
"      Flemex AC (TH);",
"     </li>",
"     <li>",
"      Flucil (TH);",
"     </li>",
"     <li>",
"      Fluimicil (CH, DE);",
"     </li>",
"     <li>",
"      Fluimiquil (LU);",
"     </li>",
"     <li>",
"      Fluimucil (AR, BG, BR, CL, CO, CZ, EC, HK, HU, ID, IT, MA, NL, PE, PL, RU, SG, TH, TW);",
"     </li>",
"     <li>",
"      Fluimucil A (MY, PK);",
"     </li>",
"     <li>",
"      Fluimukan (HR);",
"     </li>",
"     <li>",
"      Flumil (ES);",
"     </li>",
"     <li>",
"      Flumixol (CO);",
"     </li>",
"     <li>",
"      Flutafin (TW);",
"     </li>",
"     <li>",
"      Hidonac (ID, MY, PH, TH, TW);",
"     </li>",
"     <li>",
"      Icystein (TW);",
"     </li>",
"     <li>",
"      L-Cimexyl (SG);",
"     </li>",
"     <li>",
"      Lubrisec (AR);",
"     </li>",
"     <li>",
"      Lysomucil (LU);",
"     </li>",
"     <li>",
"      Lysox (LU);",
"     </li>",
"     <li>",
"      Madame Pearl's Mucolytic (HK);",
"     </li>",
"     <li>",
"      Menaxol (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Menaxol Forte (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Muclear (TH);",
"     </li>",
"     <li>",
"      Mucocar (PE);",
"     </li>",
"     <li>",
"      Mucochem (CO);",
"     </li>",
"     <li>",
"      Mucofillin (JP);",
"     </li>",
"     <li>",
"      Mucolair (LU);",
"     </li>",
"     <li>",
"      Mucolator (LU, MY);",
"     </li>",
"     <li>",
"      Mucolitico (CN);",
"     </li>",
"     <li>",
"      Mucomiste (PT);",
"     </li>",
"     <li>",
"      Mucomyst (AT, AU, BE, DK, FI, FR, KP, LU, NL, NO, SE);",
"     </li>",
"     <li>",
"      Mucomystendo (FR);",
"     </li>",
"     <li>",
"      Mucoserin (KP);",
"     </li>",
"     <li>",
"      Mucosof (CL);",
"     </li>",
"     <li>",
"      Mucosten (KP);",
"     </li>",
"     <li>",
"      Mucosys (IN);",
"     </li>",
"     <li>",
"      Mucoza (TH);",
"     </li>",
"     <li>",
"      Mucylin (ID);",
"     </li>",
"     <li>",
"      Mukolit (ID);",
"     </li>",
"     <li>",
"      Muterin (KP);",
"     </li>",
"     <li>",
"      Muxatil (PY);",
"     </li>",
"     <li>",
"      Mysoven (TH);",
"     </li>",
"     <li>",
"      N-Acc (ID);",
"     </li>",
"     <li>",
"      NAC (TR);",
"     </li>",
"     <li>",
"      NAC-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Parvolex (GB, IE, NZ);",
"     </li>",
"     <li>",
"      Pectocil (ID);",
"     </li>",
"     <li>",
"      Pectomucil (LU);",
"     </li>",
"     <li>",
"      Reolin (IL);",
"     </li>",
"     <li>",
"      Rumicil (LU);",
"     </li>",
"     <li>",
"      Sebron (KP);",
"     </li>",
"     <li>",
"      Simucil (ID);",
"     </li>",
"     <li>",
"      Simucin (TH);",
"     </li>",
"     <li>",
"      Siran 200 (IL);",
"     </li>",
"     <li>",
"      Solmucol (HU, LU, SG);",
"     </li>",
"     <li>",
"      Spatam (SG);",
"     </li>",
"     <li>",
"      Sputopur (HU);",
"     </li>",
"     <li>",
"      Stecin (KP);",
"     </li>",
"     <li>",
"      Stenac (MY);",
"     </li>",
"     <li>",
"      Tancore (TW);",
"     </li>",
"     <li>",
"      Touxium Mucolyticum (LU);",
"     </li>",
"     <li>",
"      Viskoferm (SE);",
"     </li>",
"     <li>",
"      Zifluvis (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F130130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exerts mucolytic action through its free sulfhydryl group which opens up the disulfide bonds in the mucoproteins thus lowering mucous viscosity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     In patients with acetaminophen toxicity, acetylcysteine acts as a hepatoprotective agent by restoring hepatic glutathione, serving as a glutathione substitute, and enhancing the nontoxic sulfate conjugation of acetaminophen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     The presumed mechanism in preventing contrast-induced nephropathy is its ability to scavenge oxygen-derived free radicals and improve endothelium-dependent vasodilation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F130148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Inhalation: 5-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Inhalation: &gt;1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 0.47 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 83%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reduced acetylcysteine: 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Total acetylcysteine: Adults: 5.6 hours; Newborns: 11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACT Investigators, &ldquo;Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography: Main Results from the Randomized Acetylcysteine for Contrast-induced Nephropathy Trial (ACT),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(11):1250-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/21859972/pubmed\" id=\"21859972\" target=\"_blank\">",
"        21859972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Allaqaband S, Tumuluri R, Malik AM, et al, &ldquo;Prospective Randomized Study of N-Acetylcysteine, Fenoldopam, and Saline for Prevention of Radiocontrast-Induced Nephropathy,&rdquo;",
"      <i>",
"       Catheter Cardiovasc Interv",
"      </i>",
"      , 2002, 57(3):279-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/12410497/pubmed\" id=\"12410497\" target=\"_blank\">",
"        12410497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Appelboam AV, Dargan PI, and Knighton J, &ldquo;Fatal Anaphylactoid Reaction to N-Acetylcysteine: Caution in Patients With Asthma,&rdquo;",
"      <i>",
"       Emerg Med J",
"      </i>",
"      , 2002, 19(6):594-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/12410497/pubmed\" id=\"12410497\" target=\"_blank\">",
"        12410497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B and McGuigan MA, &ldquo;Management of Anaphylactoid Reactions to Intravenous N-Acetylcysteine,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1998, 31(6):710-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/12421803/pubmed\" id=\"12421803\" target=\"_blank\">",
"        12421803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker CS, Wragg A, Kumar S, et al, \"A Rapid Protocol for the Prevention of Contrast-Induced Renal Dysfunction: The RAPPID Study,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2003, 41(12):2114-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/9624310/pubmed\" id=\"9624310\" target=\"_blank\">",
"        9624310",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Briguori C, Airoldi F, D&rsquo;Andrea D, et al, &ldquo;Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL). A Randomized Comparison of 3 Preventive Strategies,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 115(10):1211-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/17309916/pubmed\" id=\"17309916\" target=\"_blank\">",
"        17309916",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Curhan GC, &ldquo;Prevention of Contrast Nephropathy,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(5):606-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/12821233/pubmed\" id=\"12821233\" target=\"_blank\">",
"        12821233",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dart RC, Erdman AR, Olson KR, et al, &ldquo;Acetaminophen Poisoning: An Evidence-Based Consensus Guideline for Out-of-Hospital Management,&rdquo;",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2006, 44(1):1-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/12578494/pubmed\" id=\"12578494\" target=\"_blank\">",
"        12578494",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Douglas D and Smilkstein M, &ldquo;Deferoxamine-Iron Induced Pulmonary Injury and N-Acetylcysteine,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1995, 33(5):495.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/16496488/pubmed\" id=\"16496488\" target=\"_blank\">",
"        16496488",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Falk JL, &ldquo;Oral N-Acetylcysteine Given Intravenously for Acetaminophen Overdose: We Shouldn't Have To, But We Must,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1998, 26(1):7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/9428532/pubmed\" id=\"9428532\" target=\"_blank\">",
"        9428532",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harrison PM, Keays R, Bray BP, et al, &ldquo;Improved Outcome of Paracetamol-Induced Fulminant Hepatic Failure by Late Administration of Acetylcysteine,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1990, 335(8705):1572-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/9428532/pubmed\" id=\"9428532\" target=\"_blank\">",
"        9428532",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Toxicology Investigator Network Authorship Group, \"A Multicenter Comparison of the Safety of Oral Versus Intravenous Acetylcysteine for Treatment of Acetaminophen Overdose,\"",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2010, 48(5):424-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/20524832/pubmed\" id=\"20524832\" target=\"_blank\">",
"        20524832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hendrickson RG and Bizovi KE, &ldquo;Acetaminophen,&rdquo;",
"      <i>",
"       Goldfrank's Toxicologic Emergencies",
"      </i>",
"      , 8th edition, Flomenbaum NE, Goldfrank LR, Hoffman RS, et al, eds, New York: The McGraw-Hill Companies, Inc, 2006, 523-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jones AL, &ldquo;Mechanism of Action and Value of N-Acetylcysteine in the Treatment of Early and Late Acetaminophen Poisoning: A Critical Review,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1998, 36(4):277-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/9711192/pubmed\" id=\"9711192\" target=\"_blank\">",
"        9711192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jones AL, &ldquo;Recent Advances in the Management of Late Paracetamol Poisoning,&rdquo;",
"      <i>",
"       Emerg Med",
"      </i>",
"      , 2000, 12(1):14-21.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kay J, Chow WH, Chan TM, et al, &ldquo;Acetylcysteine for Prevention of Acute Deterioration of Renal Function Following Elective Coronary Angiography and Intervention: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(5):553-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/7803886/pubmed\" id=\"7803886\" target=\"_blank\">",
"        7803886",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keays R, Harrison PM, Wendon JA, et al, &ldquo;Intravenous Acetylcysteine in Paracetamol Induced Fulminant Hepatic Failure: A Prospective Controlled Trial,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1991, 303(6809):1026-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/12578487/pubmed\" id=\"12578487\" target=\"_blank\">",
"        12578487",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marenzi G, Assanelli E, Marana I, et al, &ldquo;N-Acetylcysteine and Contrast-Induced Nephropathy in Primary Angioplasty,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(26):2773-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/6807414/pubmed\" id=\"6807414\" target=\"_blank\">",
"        6807414",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mascarenhas MR, &ldquo;Treatment of Gastrointestinal Problems in Cystic Fibrosis,&rdquo;",
"      <i>",
"       Curr Treat Options Gastroenterol",
"      </i>",
"      , 2003, 6(5):427-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/1954453/pubmed\" id=\"1954453\" target=\"_blank\">",
"        1954453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mohammed S, Jamal AZ, and Robison LR, &ldquo;Serum Sickness-Like Illness Associated With N-Acetylcysteine Therapy,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1994, 28(2):285.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/12954149/pubmed\" id=\"12954149\" target=\"_blank\">",
"        12954149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mroz L, Benitez JG, and Krenzelok E, &ldquo;Angioedema With Oral Acetylcysteine,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1997, 30(2):240-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/9250658/pubmed\" id=\"9250658\" target=\"_blank\">",
"        9250658",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pakravan N, Waring WS, Sharma S, et al, &ldquo;Risk Factors and Mechanisms of Anaphylactoid Reactions to Acetylcysteine in Acetaminophen Overdose,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 2008, 46(8):697-702.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/18803085/pubmed\" id=\"18803085\" target=\"_blank\">",
"        18803085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prescott LF, Donovan JW, Jarvie DR, et al, &ldquo;The Disposition and Kinetics of Intravenous N-Acetylcysteine in Patients With Paracetamol Overdosage,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1989, 37(5):501-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/2598989/pubmed\" id=\"2598989\" target=\"_blank\">",
"        2598989",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prescott LF, Illingworth RN, Critchley JA, et al, &ldquo;Intravenous N-Acetylcysteine: The Treatment of Choice for Paracetamol Poisoning,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1979, 2:1097-1100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/2598989/pubmed\" id=\"2598989\" target=\"_blank\">",
"        2598989",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rashid ST, Salman M, Myint F, et al,&ldquo;Prevention of Contrast-Induced Nephropathy in Vascular Patients Undergoing Angiography: A Randomized Controlled Trial of Intravenous N-Acetylcysteine,\"",
"      <i>",
"       J Vasc Surg",
"      </i>",
"      , 2004, 40(6):1136-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/15622367/pubmed\" id=\"15622367\" target=\"_blank\">",
"        15622367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Rationale, Design, and Baseline Characteristics of the Acetylcystein for Contrast-Induced NephropaThy (ACT) Trial: A Pragmatic Randomized Controlled Trial to Evaluate the Efficacy of Acetylcysteine for the Prevention of Contrast-Induced Nephropathy,&rdquo;",
"      <i>",
"       Trials",
"      </i>",
"      , 2009, 10:38-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/19497091/pubmed\" id=\"19497091\" target=\"_blank\">",
"        19497091",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodgers G, Matyunas N, Ross M, et al, &ldquo;Sulfhemoglobinemia Associated With N-Acetylcysteine (NAC) Therapy of Acetaminophen (APAP) Overdose: A Case Report,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):530.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/15622367/pubmed\" id=\"15622367\" target=\"_blank\">",
"        15622367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sandilands EA and Bateman DN, &ldquo;Adverse Reactions Associated With Acetylcysteine,&rdquo;",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2009, 47(2):81-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/19280424/pubmed\" id=\"19280424\" target=\"_blank\">",
"        19280424",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmidt LE, Knudsen TT, Dalhoff K, et al, &ldquo;Effect of Acetylcysteine on Prothrombin Index in Paracetamol Poisoning Without Hepatocellular Injury,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9340):1151-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/12387966/pubmed\" id=\"12387966\" target=\"_blank\">",
"        12387966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smilkstein MJ, Bronstein AC, Linden C, &ldquo;Acetaminophen Overdose: A 48-Hour Intravenous N-Acetylcysteine Treatment Protocol,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1991, 20(10):1058-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/1928874/pubmed\" id=\"1928874\" target=\"_blank\">",
"        1928874",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smilkstein MJ, Knapp GL, Kulig KW, et al, &ldquo;Efficacy of N-Acetylcysteine in the Treatment of Acetaminophen Overdose: Analysis of the National Multicenter Study (1976 to 1985),&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1988, 319(24):1557-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/1928874/pubmed\" id=\"1928874\" target=\"_blank\">",
"        1928874",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tepel M, van der Giet M, Schwarzfeld C, et al, &ldquo;Prevention of Radiographic-Contrast-Agent-Induced Reductions in Renal Function by Acetylcysteine,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 343(3):180-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/3059186/pubmed\" id=\"3059186\" target=\"_blank\">",
"        3059186",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walson PD and Groth JF Jr, &ldquo;Acetaminophen Hepatotoxicity After Prolonged Ingestion,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 91(5):1021-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/10900277/pubmed\" id=\"10900277\" target=\"_blank\">",
"        10900277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waring WS, Stephen AF, Robinson OD, et al,&ldquo;Lower Incidence of Anaphylactoid Reactions to N-Acetylcysteine in Patients With High Acetaminophen Concentrations After Overdose,&rdquo;",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2008, 46(6):496-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/18584360/pubmed\" id=\"18584360\" target=\"_blank\">",
"        18584360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Webb JG, Pate GE, Humphries KH, et al, &ldquo;A Randomized Controlled Trial of Intravenous N-Acetylcysteine for the Prevention of Contrast-Induced Nephropathy After Cardiac Catheterization: Lack of Effect,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2004, 148(3):422-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/15389228/pubmed\" id=\"15389228\" target=\"_blank\">",
"        15389228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Woo OF, Anderson IB, Kim SY, et al, &ldquo;Shorter Duration of N-Acetylcysteine (NAC) for Acute Acetaminophen Poisoning,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):508.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/15389228/pubmed\" id=\"15389228\" target=\"_blank\">",
"        15389228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Woo OF, Mueller PD, Olson KR, et al, &ldquo;Shorter Duration of Oral N-Acetylcysteine Therapy for Acute Acetaminophen Overdose,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2000, 35(4):363-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/10736123/pubmed\" id=\"10736123\" target=\"_blank\">",
"        10736123",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yankaskas JR, Marshall BC, Sufian B, et al, &ldquo;Cystic Fibrosis Adult Care: Consensus Conference Report,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2004, 125(1 Suppl):1-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/10736123/pubmed\" id=\"10736123\" target=\"_blank\">",
"        10736123",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yip L, Dart RC, and Hurlbut KM, &ldquo;Intravenous Administration of Oral N-Acetylcysteine,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1998, 26(1):40-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/14718408/pubmed\" id=\"14718408\" target=\"_blank\">",
"        14718408",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zyoud SH, Awang R, Sulaiman SA, et al, &ldquo;Incidence of Adverse Drug Reactions Induced by N-Acetylcysteine in Patients With Acetaminophen Overdose,&rdquo;",
"      <i>",
"       Hum Exp Toxicol",
"      </i>",
"      , 2010, 29(3):153-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/20071472/pubmed\" id=\"20071472\" target=\"_blank\">",
"        20071472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zyoud SH, Awang R, Sulaiman SA, et al, &ldquo;N-Acetylcysteine-Induced Headache in Hospitalized Patients With Acute Acetaminophen Overdose,&rdquo;",
"      <i>",
"       Fundam Clin Pharmacol",
"      </i>",
"      , 2011, 25(3):405-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/1/20504/abstract-text/20584210/pubmed\" id=\"20584210\" target=\"_blank\">",
"        20584210",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9317 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_1_20504=[""].join("\n");
var outline_f20_1_20504=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130167\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130168\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130213\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130171\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130194\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130172\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671280\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671281\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130142\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130127\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130146\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130220\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130145\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130210\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130222\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130211\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130149\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130131\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298677\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130136\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130138\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130152\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130177\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130151\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130140\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130153\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130130\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130148\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9317\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9317|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/12/7365?source=related_link\">",
"      Acetylcysteine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=related_link\">",
"      Acetylcysteine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_1_20505="Psychotherapy for generalized anxiety disorder";
var content_f20_1_20505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Psychotherapy for generalized anxiety disorder",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/1/20505/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/1/20505/contributors\">",
"     Michelle Craske, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/1/20505/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/1/20505/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/1/20505/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/1/20505/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/1/20505/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15673072\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized anxiety disorder (GAD) is characterized by excessive worry and anxiety that are difficult to control, cause significant distress and impairment, and occur on more days than not for at least six months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Generalized anxiety disorder (GAD) is a relatively common disorder, most often with an adult onset and chronic course [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. GAD can lead to significant impairments in role functioning, diminished quality of life, and high healthcare costs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The disorder can be effectively treated with psychotherapy, medication, or a combination of the two modalities.",
"   </p>",
"   <p>",
"    This topic addresses psychotherapy for GAD. Pharmacotherapy for GAD is addressed separately. The epidemiology, pathogenesis, clinical manifestations, course, and diagnosis of GAD are addressed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=see_link\">",
"     \"Pharmacotherapy for generalized anxiety disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4531280\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have found cognitive behavioral therapy to be effective for generalized anxiety disorder (GAD) compared to control conditions and other psychotherapies. Evidence from clinical trials of other psychotherapies for GAD is insufficient to recommend their use. Evidence from clinical trials suggests that the combination of cognitive behavioral therapy and either benzodiazepines or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    is more effective in GAD than the medications alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673212\">",
"    <span class=\"h1\">",
"     COGNITIVE BEHAVIORAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673079\">",
"    <span class=\"h2\">",
"     Theoretical foundation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive behavioral therapy (CBT) is based on evidence that shows that persons with generalized anxiety disorder (GAD) engage in overestimations and catastrophizing of negative events; show limited confidence in problem solving; require additional evidence before making decisions; have a low tolerance of uncertainty, an iterative problem-solving style, worry about worry, and numerous behavioral and cognitive strategies that may actually be counterproductive and help maintain the self-perpetuating cycle of worry [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In particular, GAD is associated with judgment biases and attentional biases, such as a tendency to interpret ambiguous situations in a threatening manner [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], overestimate the likelihood of negative events [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/11\">",
"     11",
"    </a>",
"    ], and over-attend to threatening stimuli, even when the stimuli are not consciously perceived [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/12\">",
"     12",
"    </a>",
"    ]. The automaticity of this pre-attentive bias is likely to lead to the experience of worry and anxiety as being intrusive.",
"   </p>",
"   <p>",
"    GAD is also associated with avoidance behaviors, including excessive preparation (eg, getting to an appointment an hour beforehand to avoid being late), checking behaviors (eg, making sure the children are safe when sleeping), and procrastination [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/13\">",
"     13",
"    </a>",
"    ]. These behaviors are believed to reinforce anxiety and propagate the cycle of worry. In addition, persons with GAD may attempt to control worry by distraction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/14\">",
"     14",
"    </a>",
"    ]. The relief from distraction, however, is likely to be short-lived [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/15-17\">",
"     15-17",
"    </a>",
"    ], and attempts to deliberately suppress worry may serve to automatically prime the worry thoughts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Worry may function as an avoidance behavior in and of itself, and in particular, avoidance of fearful imagery and autonomic arousal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/18\">",
"     18",
"    </a>",
"    ]. The largely verbal, left-hemispheric act of worry is far less autonomically arousing than right-hemispheric, pictorial processing (eg, worrying about children&rsquo;s safety versus picturing them dead in a car accident) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/19\">",
"     19",
"    </a>",
"    ]. Verbal or linguistic processing of threat is associated with weaker negative affect [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/20\">",
"     20",
"    </a>",
"    ] and less autonomic reactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/21\">",
"     21",
"    </a>",
"    ] than imagery based processing of the same threat. Also, chronic worry or GAD is associated with sustained restriction of autonomic reactivity, or less variation in autonomic state [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/22\">",
"     22",
"    </a>",
"    ]. By suppressing catastrophic imagery and associated autonomic activation, worry inhibits access to underlying fear. In other words, worry becomes a form of avoidance. Catastrophic images are presumed to continue to emerge periodically, in turn motivating continued cognitive avoidance in the form of worry. As a result of this negative reinforcement cycle, pre-attentive biases towards threat and further catastrophic images, with the associated drive to shift to worry in order to avoid them, are reinforced.",
"   </p>",
"   <p>",
"    Also characteristic of GAD is low confidence in problem-solving abilities, partially due to worries over making the &ldquo;wrong&rdquo; decision. Patients with GAD prefer to acquire as much evidence as possible before making decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/23\">",
"     23",
"    </a>",
"    ], have a low tolerance for ambiguity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/24\">",
"     24",
"    </a>",
"    ], and engage in an iterative style of problem solving (ie, generating all possible negative outcomes) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/25\">",
"     25",
"    </a>",
"    ] compared to nonanxious controls. Such behavioral patterns contribute to distress over decision making and general anxiety. This is compounded by the effects of continuous worry upon ability to concentrate (eg, at work), thereby impairing performance and providing additional sources of worry.",
"   </p>",
"   <p>",
"    Positive and negative metacognitive beliefs about worry promote further worry and rumination [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/13\">",
"     13",
"    </a>",
"    ]. Positive beliefs refer to the positive value of worrying in order to reach solutions or prevent negative events from occurring. Negative beliefs that worrying is uncontrollable and harmful (ie, &ldquo;I&rsquo;m out of control to worry this excessively&rdquo;) appear to more strongly predict pathological worry compared to positive beliefs [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/26\">",
"     26",
"    </a>",
"    ], presumably because the negative beliefs generate worry about worry, attempts to suppress further worry, avoidance behaviors, and reassurance seeking [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CBT addresses the various cognitive, behavioral, and physiological features of GAD through a number of strategies. First, overestimations and catastrophizing of negative events are addressed through cognitive skills that encourage evidence-based thinking, which in turn is believed to lessen attentional biases to threat. Deficits in problem solving are targeted through additional cognitive skills that encourage a problem-coping focus, as well as behavioral skills for enhanced decision making and time management. Behavioral practices aim to reduce excessive checking, procrastination, and other &lsquo;worry&rsquo; behaviors, and often include repeated exposure to anxiety-provoking situations. In addition, through repeated exposure to catastrophic images, the emotional response and autonomic arousal subsides, which in turn reduces the drive to shift to excessive worry to avoid such images. Finally, progressive muscle relaxation aims to reduce excessive muscle tension and vigilance to threat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673086\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals for whom CBT works best are generally highly motivated and value a problem-solving approach. CBT requires that the patient learns the skills of self-observation and of becoming a personal scientist, cognitive and behavioral coping skills, and to repeatedly practice the skills in anxiety-provoking contexts outside of the therapy setting [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear whether CBT is better suited to individuals from certain cultures. CBT as a general approach is heavily aligned with Europe and North American values of an individual&rsquo;s capacity for change, open self-disclosure, independence, autonomy, and rational thinking [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/28\">",
"     28",
"    </a>",
"    ]. Such values often are at odds with values of harmony, family, and spirituality that are deeply embedded in Asian, Latino, Arabic, African American, and other cultures, which might imply that CBT would be less effective in such populations. However, evidence suggests that CBT for anxiety (although not specifically for GAD) can be effective with Latino and African American groups. Adaptation of the therapy to other cultures has been attempted (eg, greater involvement of family members), but the impact of these modifications is not well understood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exposure to anxiety-producing situations may be contraindicated for persons with dementia, psychosis, and other thought disorders.",
"   </p>",
"   <p>",
"    In patients with medical conditions potentially exacerbated by high levels of autonomic arousal (eg, certain arrhythmias or high blood pressure), a more graduated approach may be preferable to intensive exposure, with ongoing monitoring of medical status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673093\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;An in-depth, structured interview is the first step in establishing diagnostic features and details of associated behaviors (eg, decision-making difficulties) in preparation for psychotherapy. An instrument such as the Anxiety Disorders Interview Schedule, Fourth Edition (ADIS-IV) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/30\">",
"     30",
"    </a>",
"    ] can be used to collect data on the domains of worry as well as GAD physical symptoms. Such information is particularly helpful for tailoring treatment. As an example, details about the domains of worry will inform the content of cognitive restructuring.",
"   </p>",
"   <p>",
"    The most useful standardized self-report inventory is the GAD-7 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/31\">",
"     31",
"    </a>",
"    ], which is a brief scale of frequency of cognitive and somatic symptoms of GAD. Other scales, listed below, provide useful information for treatment planning and are sensitive markers of therapeutic change:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Penn State Worry Questionnaire [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/32\">",
"       32",
"      </a>",
"      ] measures the excessiveness and uncontrollable nature of worry.",
"     </li>",
"     <li>",
"      Worry Domains Questionnaire [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/33\">",
"       33",
"      </a>",
"      ] assesses the amount of worry across five domains of everyday concern: relationships, lack of confidence, aimless future, work, and financial issues.",
"     </li>",
"     <li>",
"      Metacognitions Questionnaire [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/34,35\">",
"       34,35",
"      </a>",
"      ] measures individual differences in a selection of metacognitive beliefs, judgments, and monitoring tendencies involving cognitive confidence, positive beliefs about worry, cognitive self-consciousness, negative beliefs about uncontrollability of thoughts and danger, and beliefs about need to control thoughts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673100\">",
"    <span class=\"h2\">",
"     Principles of practice",
"    </span>",
"    &nbsp;&mdash;&nbsp;The central focus of CBT for GAD is teaching patients a set of cognitive and somatic coping skills to effectively manage their anxiety as they are repeatedly exposed to anxiety provoking images and activities. More specifically, patients are taught to become personal observers of their anxiety and worry. They learn to implement skills of cognitive restructuring to replace catastrophic appraisals with more evidence-based and coping oriented appraisals. They learn techniques from relaxation training to control excessive levels of tension. Then, patients are encouraged to apply the cognitive and relaxation skills during exposures to images of feared negative events, and to anxiety-provoking situations, as they prevent themselves from engaging in overt and subtle avoidance behaviors.",
"   </p>",
"   <p>",
"    Symptoms of GAD that CBT addresses are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cognitive symptoms of excessive and uncontrollable worry about a number of different life domains",
"     </li>",
"     <li>",
"      Physical symptoms of motor tension, vigilance, restlessness, inability to relax, poor sleep, and poor concentration",
"     </li>",
"     <li>",
"      Behavioral symptoms of excessive preparation, procrastination, poor decision making, and avoidance",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673107\">",
"    <span class=\"h2\">",
"     Specific techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT is a multimodal intervention for GAD, including patient education, self-monitoring, relaxation training, cognitive restructuring, imagery exposure, exposure to anxiety provoking situations, and relapse prevention. These techniques are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673114\">",
"    <span class=\"h3\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment begins with education on:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Informing and correcting misconceptions regarding anxiety, worry, and associated symptoms",
"     </li>",
"     <li>",
"      Causative factors of pathological worry and anxiety",
"     </li>",
"     <li>",
"      A model of factors that perpetuate GAD",
"     </li>",
"     <li>",
"      The treatment plan and rationale (ie, symptoms of GAD will subside by using evidence-based and coping oriented thinking, by dealing directly with anxiety provoking images and situations, and by learning to relax)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Much of this information is integrated in presenting how a pathological cycle of worry and anxiety develops and is maintained in patients&rsquo; lives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673121\">",
"    <span class=\"h3\">",
"     Self-monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Self-monitoring is introduced in the first treatment session and continues throughout the entire treatment. Learning to observe their reactions from an objective standpoint encourages the patient&rsquo;s development as a personal scientist and increases his or her accuracy in self-observation. Self-monitoring allows patients to chart their progress in therapy.",
"   </p>",
"   <p>",
"    Patients keep track of significant episodes of worry on a Worry Record (",
"    <a class=\"graphic graphic_form graphicRef83340 \" href=\"UTD.htm?22/23/22910\">",
"     form 1",
"    </a>",
"    ) to be completed as soon as possible during or after each worry episode. The record provides a description of the cues, maximal distress, and symptoms, thoughts, and behaviors. Patients additionally complete a daily mood record at the end of each day to record overall or average levels of anxiety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673128\">",
"    <span class=\"h3\">",
"     Relaxation training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relaxation training can be particularly meaningful for GAD patients as they often experience elevated muscle tension and reduced flexibility of autonomic functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/36\">",
"     36",
"    </a>",
"    ]. Relaxation training consists of progressive muscle relaxation (after brief deliberate tension) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/37\">",
"     37",
"    </a>",
"    ] of all muscle groups of the body in a systematic manner, beginning with 16 muscle groups, and then condensing to 8 muscle groups, and 4 muscle groups.",
"   </p>",
"   <p>",
"    Relaxation training ends with cue-control relaxation, where patients cue themselves to relax by simply repeating a word (such as &ldquo;relax&rdquo;) that has been repeatedly paired with relaxation phases during the preceding weeks of progressive muscle relaxation training. Cue-control relaxation is then used as a coping skill for practicing exposure to anxiety-producing images or situations (also referred to as &ldquo;applied relaxation&rdquo;). Breathing exercises, such as slow, diaphragmatic breathing, may be incorporated into relaxation training.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673135\">",
"    <span class=\"h3\">",
"     Cognitive restructuring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive restructuring is a set of skills for identifying and modifying misappraisals that contribute to anxiety, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients are shown how anxiety and maladaptive behaviors are generated by overly-negative interpretations of events.",
"     </li>",
"     <li>",
"      Patients are helped to identify errors in thinking (eg, overestimating the probability or valence of negative events) and rigid rules or beliefs that underlie dysfunctional thought patterns.",
"     </li>",
"     <li>",
"      Patients are encouraged to use an empirical approach to examine the validity of thoughts by considering all of the available evidence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therapists use Socratic questioning to help patients make guided discoveries and question their anxious thinking. Patients then generate alternative interpretations or &ldquo;hypotheses&rdquo; to situations with the help of additional evidence gathered in behavioral practices in anxiety-provoking situations. As an example, a person who typically avoided taking on new responsibilities due to worries about making mistakes was encouraged to take on new responsibilities, to gather evidence on what happens subsequently. He or she learned that mistakes were less frequent than anticipated and did not have negative consequences. Underlying beliefs (eg, &ldquo;I am incompetent&rdquo;) are postulated to change with the patient&rsquo;s accrual of evidence that challenges his or her negative thoughts.",
"   </p>",
"   <p>",
"    Cognitive bias modification programs have been developed using paradigms initially developed to assess biases in attention (ie, dot probe) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/10\">",
"     10",
"    </a>",
"    ]. In the modification programs, individuals are trained to attend to neutral (instead of negative) words or images.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673142\">",
"    <span class=\"h3\">",
"     Imagery exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imagery exposure is designed to help patients tolerate negative affect and autonomic arousal associated with fearful images that they often attempt to avoid through worry [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients generate hierarchies of fear images related to two or three main areas of worry and are led through systematic exposure to these images. When anxiety elicited by an image is reduced to a mild level, then patients progress to the next image on the hierarchy.",
"   </p>",
"   <p>",
"    Two main versions of imagery exposure have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one version, patients imagine a worst case scenario for 25 to 30 minutes, and then generate alternative outcomes to the scenario. This approach has been shown to be effective for GAD as a standalone treatment in a small randomized trial [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The second version, self-controlled desensitization, involves utilization of cognitive restructuring and relaxation skills during imagery exposure to anxiety-provoking situations. It has been incorporated into CBT in a number of studies [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673149\">",
"    <span class=\"h3\">",
"     Exposure to anxiety-provoking situations",
"    </span>",
"    &nbsp;&mdash;&nbsp;This technique involves repeated exposure to situations that are avoided or engaged in with excessive preparation or checking. Patients generate a hierarchy of situations or activities. Examples include allowing children to have sleep overs, family vacations, arriving on time (instead of excessively early) at scheduled appointments, taking on responsibilities, or saying &lsquo;no&rsquo; to requests. Patients rehearse cognitive restructuring and relaxation coping skills in session. Subsequently, they practice using these techniques to manage anxiety in situations that occur between sessions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673156\">",
"    <span class=\"h3\">",
"     Additional components",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other techniques that may be incorporated into CBT for GAD include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Problem-solving to combat indecisiveness and increase the ability to generate alternative solutions to problems [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/43\">",
"       43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Time management training and goal setting to facilitate present task accomplishment instead of allowing worry to dominate [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673163\">",
"    <span class=\"h3\">",
"     Relapse prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;A final step in CBT is relapse prevention, in which patients are informed that recurrences of worry, anxiety or avoidance behavior are likely to occur in the future. They are encouraged to view such recurrences as lapses rather than failure, and to reapply their coping skills and reinstitute their practice of exposure to images of negative outcomes and anxiety-provoking situations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673170\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A carefully conducted 2005 meta-analysis of 65 randomized and nonrandomized controlled trials with 7739 participants found that CBT was effective for GAD, superior to no treatment (effect size = 0.82) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/45\">",
"     45",
"    </a>",
"    ]. Other meta-analyses have identified effect sizes for CBT compared to other control conditions: waiting list and placebo controls (effect size = 1.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/46\">",
"     46",
"    </a>",
"    ] and placebo controls only (effect size = 0.44 to 0.57) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment effects from CBT have been found to persist for 6 to 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/45,48\">",
"     45,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical trials published since 2005 found an average response rate of 56 percent (range = 44 to 71 percent) at the end of treatment and 57 percent (range =39 to 76 percent) at 6- to 12-month follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/42,49-54\">",
"     42,49-54",
"    </a>",
"    ]. These rates reflect complete samples in all but one case [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/52\">",
"     52",
"    </a>",
"    ], with average attrition at 10.7 percent (range = 0 to 23 percent).",
"   </p>",
"   <p>",
"    CBT has been found to be more effective than nondirective supportive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/39,55\">",
"     39,55",
"    </a>",
"    ] and more effective than psychodynamic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H195858\">",
"     'Psychodynamic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several short-term economic analyses have found CBT to be cost effective [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/7\">",
"     7",
"    </a>",
"    ]. Studies have reported reductions in patient use of medication for GAD following CBT [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193791\">",
"    <span class=\"h3\">",
"     Individual components",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear which components are critical to CBT&rsquo;s effectiveness. Trials have provided evidence for the effectiveness of most of the components as stand-alone treatments. Trials comparing individual components have had mixed results. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two randomized trials and a meta-analysis suggest applied relaxation may be effective as a stand-alone treatment for GAD [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/41,49,60\">",
"       41,49,60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cognitive therapy has been shown to be an effective stand-alone treatment for GAD [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/39,58,61,62\">",
"       39,58,61,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Computerized training programs for modifying attentional bias have been shown to significantly improve GAD symptoms in several studies [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/63\">",
"       63",
"      </a>",
"      ]. However, they have not yet been compared to standard CBT for GAD, and the effect sizes are smaller than for CBT [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Self-controlled desensitization has been shown to be as effective as a stand-alone treatment in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One trial found cognitive therapy to be superior to applied relaxation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/39\">",
"       39",
"      </a>",
"      ], but other trials found cognitive therapy and applied relaxation to be equally effective [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/49,58,61\">",
"       49,58,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One trial found that multicomponent treatment was more effective than individual CBT components [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/65\">",
"       65",
"      </a>",
"      ], whereas another trial found the two comparable [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193707\">",
"    <span class=\"h3\">",
"     Children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two clinical trials have found CBT to be effective for anxiety disorders in children and adolescents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A clinical trial of a CBT, the Coping Cat Program, randomly assigned 47 children (9 to 13 years) with GAD, separation anxiety disorder, or social anxiety disorder to either CBT or waitlist control. After 16 sessions (four months of treatment), 64 percent no longer met diagnostic criteria for the anxiety disorder compared to 5 percent in the waitlist control group [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/66\">",
"       66",
"      </a>",
"      ], with results generally maintained in patients reassessed at 12-month and 3-year follow ups [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/67\">",
"       67",
"      </a>",
"      ]. Results were replicated in a second randomized trial with 94 youths [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A clinical trial in children with anxiety disorders found particularly high response rates for the combination of CBT and a family-based treatment. Seventy-nine children aged 7 to 14 with separation anxiety, overanxious disorder, or social phobia were randomly assigned to CBT, CBT plus family treatment, or waiting list status with response rates of 95.6 percent for combined CBT and family treatment, 69.8 percent for CBT alone, and 26.0 percent for the waiting list group [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/69\">",
"       69",
"      </a>",
"      ]. In another study, family involvement was most beneficial when both parents had an anxiety disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H193714\">",
"    <span class=\"h3\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rates of response of GAD to CBT are generally lower in late-life samples compared to younger adults [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/52,54,71\">",
"     52,54,71",
"    </a>",
"    ]. As an example, in a late-life sample with GAD treated with CBT in primary care, only 40 percent of the intent-to-treat sample was classified as responders [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/52\">",
"     52",
"    </a>",
"    ] compared to an average 56 percent response rate found in trials of non-late-life samples. (See",
"    <a class=\"local\" href=\"#H15673170\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Group treatment that encourages interaction and opportunities for self-disclosure may increase the efficacy of CBT in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/72\">",
"     72",
"    </a>",
"    ]. Additional treatment considerations include learning aids (eg, acronyms for techniques) and memory enhancers (eg, homework reminders, weekly reviews of techniques) to compensate for reduced short- and long-term memory abilities, fewer homework assignments, and a slower pace of CBT sessions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194680\">",
"    <span class=\"h3\">",
"     Computer-based CBT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials have found internet-based delivery of CBT with therapist support to be effective for GAD compared to waiting list controls, with effect sizes of 1.08 and 1.13. Acceptability and completion rates were high [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/73\">",
"     73",
"    </a>",
"    ]. In children (aged 7 to 13 years), computer-assisted CBT that involved the therapist did not differ from fully therapist-delivered CBT at either post or three-month follow-up in terms of symptom outcomes or treatment satisfaction, with both conditions more effective than computer-assisted education, support, and attention [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/74\">",
"     74",
"    </a>",
"    ]. In adults with mixed anxiety disorders in primary care settings, a treatment arm that was comprised largely of computer-assisted CBT delivered by a clinician combined with psychotropic medication optimization was found to be more effective than treatment as usual for patients with GAD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673177\">",
"    <span class=\"h2\">",
"     Predictors of better outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT generally appears to have comparable effectiveness in GAD across gender and socioeconomic status [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/51\">",
"     51",
"    </a>",
"    ]. Interpersonal difficulties have been found to predict poorer outcomes from CBT for GAD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/62,76\">",
"     62,76",
"    </a>",
"    ], as have poor physical health and high baseline levels of neuroticism for those with late-life anxiety including GAD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals with GAD have high rates of co-occurring psychiatric disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]; however, studies of the influence of comorbidity on the outcome of CBT for GAD are mixed. Some studies find that baseline comorbidity is associated with a worsened outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/76\">",
"     76",
"    </a>",
"    ], although a number of studies show either no effect or improved outcomes in GAD with a co-occurring disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/54,79,80\">",
"     54,79,80",
"    </a>",
"    ]. Research has found CBT for GAD to result in improvements in co-occurring anxiety disorders and depression [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673184\">",
"    <span class=\"h2\">",
"     Frequency and duration of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT is generally provided in 10 to 15 60-minute sessions for GAD, but can include additional sessions depending on patient&rsquo;s level of severity, the presence of comorbidity, patient resistance to the treatment approach, therapist competence, and the number of components incorporated into CBT.",
"   </p>",
"   <p>",
"    CBT treatment sessions are always accompanied by homework assignments, usually daily, to be conducted between sessions. Thus, therapy time for the patient is more extensive than the time spent in-session with therapists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673191\">",
"    <span class=\"h1\">",
"     COMBINED CBT AND MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from clinical trials suggests that the combination of CBT and either benzodiazepines [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/82,83\">",
"     82,83",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/84\">",
"     84",
"    </a>",
"    ] is more effective in GAD than the medications alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=see_link&amp;anchor=H211197366#H211197366\">",
"     \"Pharmacotherapy for generalized anxiety disorder\", section on 'Combined medication and CBT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673198\">",
"    <span class=\"h1\">",
"     COMPARING CBT TO MEDICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is insufficient evidence comparing CBT to medication for GAD to favor one modality over the other. Selection between these modalities may be based on treatment availability and patient preference. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=see_link&amp;anchor=H3471601#H3471601\">",
"     \"Pharmacotherapy for generalized anxiety disorder\", section on 'Comparing medication to CBT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673205\">",
"    <span class=\"h1\">",
"     OTHER PSYCHOTHERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although nearly all clinical trials of psychotherapy effective in GAD focus on CBT, other psychotherapies have been studied for the disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H195858\">",
"    <span class=\"h2\">",
"     Psychodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In psychodynamic approaches to GAD, treatment typically focuses upon core conflictual relationship themes. Emphasis is placed upon a positive therapeutic alliance to provide a corrective emotional experience to offset insecure attachment.",
"   </p>",
"   <p>",
"    Findings from a small clinical trial provide some evidence of effectiveness for supportive-expressive therapy, a short-term psychodynamic therapy, in GAD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/85\">",
"     85",
"    </a>",
"    ]. Thirty-one patients with GAD randomly assigned either to supportive-expressive therapy or supportive therapy showed no difference in mean GAD symptom reduction, but supportive-expressive therapy led to a higher rate of remission.",
"   </p>",
"   <p>",
"    Two clinical trials have found CBT to be more effective than psychodynamic therapy in GAD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 110 patients with GAD were randomly assigned to CBT, psychodynamic therapy, or anxiety management training [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/56\">",
"       56",
"      </a>",
"      ]. Patients in all three groups showed improvement; however, patients receiving CBT showed greater improvement than patients receiving psychodynamic therapy. This study was limited in that the delivery of CBT was supported by therapist training, an instructive manual, and fidelity assessment, while psychodynamic therapy was not [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A clinical trial comparing supportive-expressive therapy, a short-term psychodynamic",
"      <sup>",
"      </sup>",
"      therapy, and CBT in 57 patients with GAD was designed to address limitations of the previous trial [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/57\">",
"       57",
"      </a>",
"      ]. Both therapies led to large reductions in GAD symptoms, with no difference seen between the two groups in the primary outcome, the Hamilton Anxiety Rating Scale. However, CBT showed superior results on self-report measures of trait anxiety and worry [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196125\">",
"    <span class=\"h2\">",
"     Emotional regulation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emotional regulation therapy incorporates components of CBT such as psychoeducation and self-monitoring, as well as interventions that address emotion regulation (deficits prominent in GAD), emotional avoidance, and interpersonal difficulties [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/86\">",
"     86",
"    </a>",
"    ]. A clinical trial comparing CBT plus emotion-focused and interpersonal strategies with CBT plus supportive listening in 83 patients with GAD found both groups to experience reduced GAD symptoms, with no differences seen between groups [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196176\">",
"    <span class=\"h2\">",
"     Acceptance and commitment therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mindfulness-based (ie, nonjudgmental observation of moment to moment experiences) psychotherapies have been shown to be efficacious in decreasing anxiety symptoms in an uncontrolled study of individuals with GAD and panic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/87\">",
"     87",
"    </a>",
"    ]. Acceptance and Commitment Therapy (ACT) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/88\">",
"     88",
"    </a>",
"    ] combines mindfulness with acceptance of internal states and orientation of actions towards valued goals. Although there are some similarities between an ACT approach and a CBT approach [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/89\">",
"     89",
"    </a>",
"    ], ACT does not involve any form of cognitive restructuring (ie, identifying, challenging, and replacing negative thinking with more realistic thinking) or any attempt to change or correct somatic dysregulation (eg, relaxation training). A preliminary randomized trial of 16 patients supports the efficacy of an ACT approach for GAD [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20505/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15673064\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that patients with generalized anxiety disorder (GAD) be treated with cognitive behavioral therapy (CBT), a serotonergic antidepressant, or both, rather than no treatment (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). No difference in efficacy has been found between CBT and serotonergic antidepressants; selection between them can be made on the basis of patient preference and treatment availability. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=see_link&amp;anchor=H3471601#H3471601\">",
"       \"Pharmacotherapy for generalized anxiety disorder\", section on 'Comparing medication to CBT'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H15673198\">",
"       'Comparing CBT to medication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment of GAD with CBT rather than nondirective supportive therapy or psychodynamic therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) or other psychotherapies. (See",
"      <a class=\"local\" href=\"#H15673170\">",
"       'Efficacy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15673205\">",
"       'Other psychotherapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The theoretical foundation of CBT for GAD derives from research on cognitive, physiological, and behavioral features of persons with the disorder. (See",
"      <a class=\"local\" href=\"#H15673079\">",
"       'Theoretical foundation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CBT is a multimodal intervention. Specific techniques used in the therapy include education, self-monitoring, relaxation training, cognitive restructuring, exposure to imagery and anxiety-producing situations, and relapse prevention. (See",
"      <a class=\"local\" href=\"#H15673107\">",
"       'Specific techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CBT is generally provided in 10 to 15 60-minute sessions for GAD, but can include additional sessions depending on patient&rsquo;s level of severity, the presence of comorbidity, patient resistance to the treatment approach, therapist competence, and the number of components incorporated into CBT. (See",
"      <a class=\"local\" href=\"#H15673184\">",
"       'Frequency and duration of treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/2\">",
"      Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005; 15:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/3\">",
"      Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/4\">",
"      Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/5\">",
"      Bruce SE, Yonkers KA, Otto MW, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 2005; 162:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/6\">",
"      Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/7\">",
"      Bereza BG, Machado M, Einarson TR. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. Clin Ther 2009; 31:1279.",
"     </a>",
"    </li>",
"    <li>",
"     Craske MG. Origins of phobias and anxiety disorders: Why more women than men, Elsevier, Oxford 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/9\">",
"      Mathews A, Mackintosh B. Induced emotional interpretation bias and anxiety. J Abnorm Psychol 2000; 109:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/10\">",
"      Mathews A, MacLeod C. Cognitive vulnerability to emotional disorders. Annu Rev Clin Psychol 2005; 1:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/11\">",
"      Butler G, Mathews A. Anticipatory anxiety and risk perception. Cognit Ther Res 1987; 11:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/12\">",
"      Mogg K, Bradley B. Attentional bias in generalized anxiety disorder versus depressive disorder. Cognit Ther Res 2005; 29:29.",
"     </a>",
"    </li>",
"    <li>",
"     Wells A, Matthews G. Attention and Emotion: A clinical perspective, Erlbaum, Hove, UK 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/14\">",
"      Schut AJ, Castonguay LG, Borkovec TD. Compulsive checking behaviors in generalized anxiety disorder. J Clin Psychol 2001; 57:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/15\">",
"      Wegner DM, Schneider DJ, Carter SR 3rd, White TL. Paradoxical effects of thought suppression. J Pers Soc Psychol 1987; 53:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/16\">",
"      Wegner DM, Erber R. The hyperaccessibility of suppressed thoughts. J Pers Soc Psychol 1992; 63:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/17\">",
"      Wenzlaff RM, Wegner DM, Roper DW. Depression and mental control: the resurgence of unwanted negative thoughts. J Pers Soc Psychol 1988; 55:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/18\">",
"      Borkovec TD, Inz J. The nature of worry in generalized anxiety disorder: a predominance of thought activity. Behav Res Ther 1990; 28:153.",
"     </a>",
"    </li>",
"    <li>",
"     Borkovec TD. The nature, functions, and origins of worry. In: Worrying: Perspectives on theory, assessment, and treatment, Davey G, Tallis F.  (Eds), Wiley, New York 1994. p.5.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/20\">",
"      Holmes EA, Mathews A. Mental imagery in emotion and emotional disorders. Clin Psychol Rev 2010; 30:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/21\">",
"      Vrana SR, Cuthbert BN, Lang PJ. Processing fearful and neutral sentences: Memory and heart rate change. Cogn Emot 1989; 3:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/22\">",
"      Friedman BH, Thayer JF. Anxiety and autonomic flexibility: a cardiovascular approach. Biol Psychol 1998; 49:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/23\">",
"      Tallis F, Eysenck MW, Mathews A. Elevated evidence requirements and worry. Pers Individ Dif 1991; 12:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/24\">",
"      Dugas MJ, Ladouceur R, L&eacute;ger E, et al. Group cognitive-behavioral therapy for generalized anxiety disorder: treatment outcome and long-term follow-up. J Consult Clin Psychol 2003; 71:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/25\">",
"      Startup HM, Davey GC. Mood as input and catastrophic worrying. J Abnorm Psychol 2001; 110:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/26\">",
"      Wells A, Carter K. Preliminary tests of a cognitive model of generalized anxiety disorder. Behav Res Ther 1999; 37:585.",
"     </a>",
"    </li>",
"    <li>",
"     Craske MG. Cognitive behavior therapy, American Psychological Association, Washington, DC 2009.",
"    </li>",
"    <li>",
"     Hays PA, Iwamasa GY. Culturally responsive cognitive behavioral therapy: Assessment, practice, and supervision, American Psychological Association, Washington, DC 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/29\">",
"      Miranda J, Bernal G, Lau A, et al. State of the science on psychosocial interventions for ethnic minorities. Annu Rev Clin Psychol 2005; 1:113.",
"     </a>",
"    </li>",
"    <li>",
"     Brown TA, Di Nardo PA, Barlow DH. Anxiety disorders interview schedule for DSM-IV (ADIS-IV), Graywind, Boulder, CO 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/31\">",
"      Spitzer RL, Kroenke K, Williams JB, L&ouml;we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/32\">",
"      Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther 1990; 28:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/33\">",
"      Tallis F, Eysenck MW, Mathews A. A questionnaire for the measurement of nonpathological worry. Pers Individ Dif 1992; 13:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/34\">",
"      Cartwright-Hatton S, Wells A. Beliefs about worry and intrusions: the Meta-Cognitions Questionnaire and its correlates. J Anxiety Disord 1997; 11:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/35\">",
"      Wells A, Cartwright-Hatton S. A short form of the metacognitions questionnaire: properties of the MCQ-30. Behav Res Ther 2004; 42:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/36\">",
"      Thayer JF, Friedman BH, Borkovec TD. Autonomic characteristics of generalized anxiety disorder and worry. Biol Psychiatry 1996; 39:255.",
"     </a>",
"    </li>",
"    <li>",
"     Bernstein DA, Borkovec TD, Hazlett-Stevens H. New editions in progressive relaxation training: A guidebook for helping professionals, Praeger, Westport, CT 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/38\">",
"      Borkovec TD, Hu S. The effect of worry on cardiovascular response to phobic imagery. Behav Res Ther 1990; 28:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/39\">",
"      Borkovec TD, Costello E. Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol 1993; 61:611.",
"     </a>",
"    </li>",
"    <li>",
"     Craske MG, Barlow DH, O&rsquo;Leary TA. Mastery of your anxiety and worry, Graywind, Boulder, CO 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/41\">",
"      Hoyer J, Beesdo K, Gloster AT, et al. Worry exposure versus applied relaxation in the treatment of generalized anxiety disorder. Psychother Psychosom 2009; 78:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/42\">",
"      Newman MG, Castonguay LG, Borkovec TD, et al. A randomized controlled trial of cognitive-behavioral therapy for generalized anxiety disorder with integrated techniques from emotion-focused and interpersonal therapies. J Consult Clin Psychol 2011; 79:171.",
"     </a>",
"    </li>",
"    <li>",
"     Stress reduction and prevention, Meichenbaum DS, Jaremko ME.  (Eds), Plenum Press, New York 1983.",
"    </li>",
"    <li>",
"     Brown TA, O&rsquo;Leary TA, Barlow DH. Generalized anxiety disorder. In: Clinical handbook of psychological disorders: A step-by-step treatment manual, Barlow DH.  (Ed), Guilford, New York 2001. p.154.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/45\">",
"      Mitte K. Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy. Psychol Bull 2005; 131:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/46\">",
"      Norton PJ, Price EC. A meta-analytic review of adult cognitive-behavioral treatment outcome across the anxiety disorders. J Nerv Ment Dis 2007; 195:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/47\">",
"      Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry 2008; 69:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/48\">",
"      Borkovec TD, Ruscio AM. Psychotherapy for generalized anxiety disorder. J Clin Psychiatry 2001; 62 Suppl 11:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/49\">",
"      Dugas MJ, Brillon P, Savard P, et al. A randomized clinical trial of cognitive-behavioral therapy and applied relaxation for adults with generalized anxiety disorder. Behav Ther 2010; 41:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/50\">",
"      Linden M, Zubraegel D, Baer T, et al. Efficacy of cognitive behaviour therapy in generalized anxiety disorders. Results of a controlled clinical trial (Berlin CBT-GAD Study). Psychother Psychosom 2005; 74:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/51\">",
"      Schuurmans J, Comijs H, Emmelkamp PM, et al. Long-term effectiveness and prediction of treatment outcome in cognitive behavioral therapy and sertraline for late-life anxiety disorders. Int Psychogeriatr 2009; 21:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/52\">",
"      Stanley MA, Wilson NL, Novy DM, et al. Cognitive behavior therapy for generalized anxiety disorder among older adults in primary care: a randomized clinical trial. JAMA 2009; 301:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/53\">",
"      Westra HA, Arkowitz H, Dozois DJ. Adding a motivational interviewing pretreatment to cognitive behavioral therapy for generalized anxiety disorder: a preliminary randomized controlled trial. J Anxiety Disord 2009; 23:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/54\">",
"      Wetherell JL, Hopko DR, Diefenbach GJ, et al. Cognitive-behavioral therapy for late-life generalized anxiety disorder: who gets better? Behav Ther 2005; 36:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/55\">",
"      Borkovec TD, Mathews AM. Treatment of nonphobic anxiety disorders: a comparison of nondirective, cognitive, and coping desensitization therapy. J Consult Clin Psychol 1988; 56:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/56\">",
"      Durham RC, Fisher PL, Treliving LR, et al. One year follow-up of cognitive therapy, analytic psychotherapy and anxiety management training for generalized anxiety disorder: symptom change, medication usage and attitudes to treatment. Behav Cogn Psychother 1999; 27:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/57\">",
"      Leichsenring F, Salzer S, Jaeger U, et al. Short-term psychodynamic psychotherapy and cognitive-behavioral therapy in generalized anxiety disorder: a randomized, controlled trial. Am J Psychiatry 2009; 166:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/58\">",
"      Ost LG, Breitholtz E. Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder. Behav Res Ther 2000; 38:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/59\">",
"      Barlow DH, Rapee RM, Brown TA. Behavioral treatment of generalized anxiety disorder. Behav Ther 1992; 23:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/60\">",
"      Siev J, Chambless DL. Specificity of treatment effects: cognitive therapy and relaxation for generalized anxiety and panic disorders. J Consult Clin Psychol 2007; 75:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/61\">",
"      Arntz A. Cognitive therapy versus applied relaxation as treatment of generalized anxiety disorder. Behav Res Ther 2003; 41:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/62\">",
"      Borkovec TD, Newman MG, Pincus AL, Lytle R. A component analysis of cognitive-behavioral therapy for generalized anxiety disorder and the role of interpersonal problems. J Consult Clin Psychol 2002; 70:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/63\">",
"      Amir N, Beard C, Burns M, Bomyea J. Attention modification program in individuals with generalized anxiety disorder. J Abnorm Psychol 2009; 118:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/64\">",
"      Hallion LS, Ruscio AM. A meta-analysis of the effect of cognitive bias modification on anxiety and depression. Psychol Bull 2011; 137:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/65\">",
"      Butler G, Fennell M, Robson P, Gelder M. Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol 1991; 59:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/66\">",
"      Kendall PC. Treating anxiety disorders in children: results of a randomized clinical trial. J Consult Clin Psychol 1994; 62:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/67\">",
"      Kendall PC, Southam-Gerow MA. Long-term follow-up of a cognitive-behavioral therapy for anxiety-disordered youth. J Consult Clin Psychol 1996; 64:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/68\">",
"      Kendall PC, Flannery-Schroeder E, Panichelli-Mindel SM, et al. Therapy for youths with anxiety disorders: a second randomized clinical trial. J Consult Clin Psychol 1997; 65:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/69\">",
"      Barrett PM, Dadds MR, Rapee RM. Family treatment of childhood anxiety: a controlled trial. J Consult Clin Psychol 1996; 64:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/70\">",
"      Kendall PC, Hudson JL, Gosch E, et al. Cognitive-behavioral therapy for anxiety disordered youth: a randomized clinical trial evaluating child and family modalities. J Consult Clin Psychol 2008; 76:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/71\">",
"      Stanley MA, Beck JG, Novy DM, et al. Cognitive-behavioral treatment of late-life generalized anxiety disorder. J Consult Clin Psychol 2003; 71:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/72\">",
"      Wetherell JL, Gatz M, Craske MG. Treatment of generalized anxiety disorder in older adults. J Consult Clin Psychol 2003; 71:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/73\">",
"      Andrews G, Cuijpers P, Craske MG, et al. Computer therapy for the anxiety and depressive disorders is effective, acceptable and practical health care: a meta-analysis. PLoS One 2010; 5:e13196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/74\">",
"      Khanna MS, Kendall PC. Computer-assisted cognitive behavioral therapy for child anxiety: results of a randomized clinical trial. J Consult Clin Psychol 2010; 78:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/75\">",
"      Craske MG, Stein MB, Sullivan G, et al. Disorder-specific impact of coordinated anxiety learning and management treatment for anxiety disorders in primary care. Arch Gen Psychiatry 2011; 68:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/76\">",
"      Durham RC, Allan T, Hackett CA. On predicting improvement and relapse in generalized anxiety disorder following psychotherapy. Br J Clin Psychol 1997; 36 ( Pt 1):101.",
"     </a>",
"    </li>",
"    <li>",
"     Holaway RM, Rodebaug TL, Heimberg RG. The epidemiology of worry and generalized anxiety disorder. In: Worry and its psychological disorders: Theory, assessment and treatment, Davey G, Wells A.  (Eds), Wiley Publishing, Hoboken, NJ 2006. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/78\">",
"      Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/79\">",
"      Butler G, Anastasiades P. Predicting response to anxiety management in patients with generalised anxiety disorders. Behav Res Ther 1988; 26:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/80\">",
"      Newman MG, Przeworski A, Fisher AJ, Borkovec TD. Diagnostic comorbidity in adults with generalized anxiety disorder: impact of comorbidity on psychotherapy outcome and impact of psychotherapy on comorbid diagnoses. Behav Ther 2010; 41:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/81\">",
"      Borkovec TD, Abel JL, Newman H. Effects of psychotherapy on comorbid conditions in generalized anxiety disorder. J Consult Clin Psychol 1995; 63:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/82\">",
"      Power KG, Simpson RJ, Swanson V, Wallace LA. A controlled comparison of cognitive-behaviour therapy, diazepam, and placebo, alone and in combination, for the treatment of generalised anxiety disorder. J Anxiety Disord 1990; 4:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/83\">",
"      Power KG, Simpson RJ, Swanson V, Wallace LA. Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care. Br J Gen Pract 1990; 40:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/84\">",
"      Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008; 359:2753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/85\">",
"      Crits-Christoph P, Connolly MB, Narducci J, et al. Interpersonal problems and the outcome of interpersonal-psychodynamic treatment of generalized anxiety disorder. Psychotherapy 2005; 42:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/86\">",
"      Mennin DS. Emotion regulation therapy for generalized anxiety disorder. Clin Psychol Psychother 2004; 11:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/87\">",
"      Kabat-Zinn J, Massion AO, Kristeller J, et al. Effectiveness of a meditation-based stress reduction program in the treatment of anxiety disorders. Am J Psychiatry 1992; 149:936.",
"     </a>",
"    </li>",
"    <li>",
"     Hayes SC, Strosahl KD, Wilson KG. Acceptance and commitment therapy: An experiental approach to behavior change, Guilford Press, New York 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/89\">",
"      Arch JJ, Craske MG. Acceptance and  commitment therapy and cognitive behavioral therapy for anxiety disorders: different treatments, similar mechanisms? Clinical Psychology: Science &amp; Practice 2008; 5:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20505/abstract/90\">",
"      Roemer L, Orsillo SM, Salters-Pedneault K. Efficacy of an acceptance-based behavior therapy for generalized anxiety disorder: evaluation in a randomized controlled trial. J Consult Clin Psychol 2008; 76:1083.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14632 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-CACC98E3A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_1_20505=[""].join("\n");
var outline_f20_1_20505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15673064\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15673072\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4531280\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15673212\">",
"      COGNITIVE BEHAVIORAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15673079\">",
"      Theoretical foundation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15673086\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15673093\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15673100\">",
"      Principles of practice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15673107\">",
"      Specific techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15673114\">",
"      - Education",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15673121\">",
"      - Self-monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15673128\">",
"      - Relaxation training",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15673135\">",
"      - Cognitive restructuring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15673142\">",
"      - Imagery exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15673149\">",
"      - Exposure to anxiety-provoking situations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15673156\">",
"      - Additional components",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15673163\">",
"      - Relapse prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15673170\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193791\">",
"      - Individual components",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193707\">",
"      - Children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H193714\">",
"      - Older adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H194680\">",
"      - Computer-based CBT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15673177\">",
"      Predictors of better outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15673184\">",
"      Frequency and duration of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15673191\">",
"      COMBINED CBT AND MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15673198\">",
"      COMPARING CBT TO MEDICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15673205\">",
"      OTHER PSYCHOTHERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H195858\">",
"      Psychodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H196125\">",
"      Emotional regulation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H196176\">",
"      Acceptance and commitment therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15673064\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14632\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14632|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?22/23/22910\" title=\"form 1\">",
"      Worry record",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2665?source=related_link\">",
"      Pharmacotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_1_20506="Hereditary spherocytosis: Clinical features; diagnosis; and treatment";
var content_f20_1_20506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hereditary spherocytosis: Clinical features; diagnosis; and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/1/20506/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/1/20506/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/1/20506/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/1/20506/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/1/20506/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/1/20506/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/1/20506/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary spherocytosis (HS) is the most common hemolytic anemia due to a red cell membrane defect. It is a result of heterogeneous alterations in one of six genes (most often the ankyrin gene) that encode for proteins involved in vertical associations that tie the membrane skeleton to the lipid bilayer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=see_link\">",
"     \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of HS will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/1\">",
"     1",
"    </a>",
"    ]. Red blood cell membrane function is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13352?source=see_link\">",
"     \"Red blood cell membrane dynamics and organization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17046?source=see_link\">",
"     \"Red blood cell mechanics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480082\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of hereditary spherocytosis is about 200 to 300 per million in northern European populations, but this is likely to be an underestimate, as mild cases are often not diagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/2\">",
"     2",
"    </a>",
"    ]. In other parts of the world the disease is thought to be less common, although comprehensive population survey data are unavailable. Family studies indicate autosomal dominant inheritance in about 75 percent of patients, with recessive inheritance occurring in most of the remaining patients. However, a significant number of patients with hematologically normal parents and presumed recessive disease prove to harbor de novo mutations that will exhibit dominant inheritance in subsequent generations [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia, jaundice, and splenomegaly are the common clinical features of HS. The degree of anemia is extremely variable and may be absent, mild, moderate, or severe to the point of threatening life [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. HS is generally classified into three forms based upon the severity of the disease process [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild HS occurs in 20 to 30 percent of cases. These patients have no anemia, modest reticulocytosis, little in the way of splenomegaly or jaundice, and the disorder may not be detected until adolescence or adult life. Subjects with mild HS maintain normal hemoglobin levels in the face of accelerated erythrocyte destruction via an erythropoietin-driven increase in erythropoiesis [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/10\">",
"       10",
"      </a>",
"      ]. The stimulus for increased production of erythropoietin is not known but does not appear to be due to hypoxia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link\">",
"       \"Regulation of erythropoiesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Moderate HS accounts for 60 to 75 percent of cases. Moderately affected individuals are anemic, have high reticulocyte counts, and elevated serum bilirubin concentrations. They may require occasional transfusions, and the condition is usually detected in infancy or childhood. Although this group of anemic patients displays an appropriate increase in serum erythropoietin, the reticulocyte response may be blunted, contributing to the degree of their anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe HS occurs in approximately 5 percent of cases. It is characterized by marked hemolysis, anemia, hyperbilirubinemia, splenomegaly, and a regular requirement for red cell transfusions [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/6\">",
"       6",
"      </a>",
"      ]. The pattern of inheritance is almost always recessive and the parents of an affected patient are usually asymptomatic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Signs and symptoms according to age",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480097\">",
"    <span class=\"h3\">",
"     In utero",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrops fetalis with death in utero can occur in the most severe cases of HS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480104\">",
"    <span class=\"h3\">",
"     Neonatal period",
"    </span>",
"    &nbsp;&mdash;&nbsp;When detected in the neonatal period, HS is commonly accompanied by jaundice, requiring treatment with phototherapy or exchange transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/6\">",
"     6",
"    </a>",
"    ]. However, most neonates have little or no anemia, reticulocytosis, or spherocytosis on the peripheral blood smear [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This is followed by a reduction in the hemoglobin concentration over the ensuing three weeks that is transient, but may be severe enough to require transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/14\">",
"     14",
"    </a>",
"    ]. Two factors are thought to be responsible for the delay in the appearance of anemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial failure to produce an appropriate erythropoietin response, as an adequate reticulocytosis cannot be mounted for several months after birth.",
"     </li>",
"     <li>",
"      Development of splenic filtering function, with progressive RBC trapping and destruction [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"       \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of hereditary spherocytosis can be suspected in newborns who are clinically jaundiced and whose mean corpuscular hemoglobin concentration (MCHC) is greater than 36",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/15\">",
"     15",
"    </a>",
"    ]. The diagnosis can be established during the entire newborn period and afterward by the Eosin-5-maleimide binding test (EMA), osmotic gradient ektacytometry (see below), or osmotic fragility testing (",
"    <a class=\"graphic graphic_figure graphicRef69042 \" href=\"UTD.htm?11/48/12047\">",
"     figure 1",
"    </a>",
"    ). It is important that the testing be compared with results of a normal control of the same age, coupled with a careful examination of the peripheral blood smear and red cell indices [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15480428\">",
"     'Osmotic fragility testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480111\">",
"    <span class=\"h3\">",
"     Infancy and adulthood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the neonatal period, jaundice is rarely intense. As in other chronic hemolytic anemias, exacerbations may be aplastic, hemolytic, or megaloblastic in origin:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An aplastic crisis may result from transient bone marrow suppression by parvovirus B19 or other viral infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=see_link\">",
"       \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increased hemolysis may accompany viral illnesses, probably due to splenomegaly associated with the illness.",
"     </li>",
"     <li>",
"      Megaloblastic anemia may be superimposed upon the chronic hemolytic anemia of HS due to an unmet increased need for folate to support erythropoiesis; this is most likely to occur in malnourished patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Splenomegaly is common in patients with HS and, in large family studies, palpable spleens are found in over 75 percent of affected members. There is no correlation between spleen size and disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gallstone formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common complication of hereditary spherocytosis is the development of bilirubin gallstones. The likelihood of cholelithiasis is directly related to patient age; it is uncommon before age 10, but is present in at least one-half of adults, particularly those with more severe hemolytic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An interesting observation is that the development of obstructive jaundice due to gallstones in HS improves the hemolytic process and normalizes osmotic fragility [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/18\">",
"     18",
"    </a>",
"    ]. In this setting, the increase in membrane surface area due to the abnormal plasma lipid profile normalizes the previously reduced surface area-to-volume ratio due to loss of membrane surface area in the spherocytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=see_link&amp;anchor=H3#H3\">",
"     \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\", section on 'Membrane instability'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9305?source=see_link&amp;anchor=H5#H5\">",
"     \"Spiculated cells (echinocytes and acanthocytes) and target cells\", section on 'Liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of gallstones is increased further if the patient with HS co-inherits the genetic defect resulting in diminished activity of the bilirubin conjugating enzyme uridine diphosphate-glucuronyl transferase (ie, Gilbert syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/19\">",
"     19",
"    </a>",
"    ]. In a study of 102 children from Southern Italy with mild to moderate HS, gallstones were found in 12, 26, and 48 percent of children who were normal, heterozygous, or homozygous for the Gilbert syndrome mutation, respectively. Although the effect was to double the incidence of gallstones for each dose of the abnormal gene, there was no significant difference in the age of onset of gallstones or the degree of hemolysis, as measured by average reticulocyte numbers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=see_link&amp;anchor=H2#H2\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\", section on 'Bilirubin overproduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480142\">",
"    <span class=\"h2\">",
"     Other complications of HS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare complications of or associations with HS include leg ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/20\">",
"     20",
"    </a>",
"    ], extramedullary hematopoietic tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], priapism [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/23\">",
"     23",
"    </a>",
"    ], spinocerebellar degenerative syndromes, hypertrophic cardiomyopathy, and movement disorder with myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/7\">",
"     7",
"    </a>",
"    ]. Complications related to splenectomy in patients with HS are discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Risks'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LABORATORY STUDIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480173\">",
"    <span class=\"h2\">",
"     Complete blood count",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine blood counts in HS reveal anemia and reticulocytosis to varying degrees, depending upon the severity of the mutation. The usual reticulocyte count is from 5 to 20 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480180\">",
"    <span class=\"h2\">",
"     Red blood cell indices",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14834620\">",
"    <span class=\"h3\">",
"     Mean corpuscular volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean corpuscular volume (MCV) is normal or slightly low and is of little diagnostic value. However, considering the degree of reticulocytosis that is present, which tends to increase the MCV, the MCV is actually low. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/45/35543?source=see_link&amp;anchor=H15#H15\">",
"     \"Mean corpuscular volume\", section on 'Reticulocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14834613\">",
"    <span class=\"h3\">",
"     Mean corpuscular hemoglobin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most helpful red cell index is the mean cell hemoglobin concentration (MCHC), which is routinely elevated, reflecting membrane loss and red cell dehydration (",
"    <a class=\"graphic graphic_table graphicRef54945 \" href=\"UTD.htm?1/50/1836\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/24\">",
"     24",
"    </a>",
"    ]. An elevated red cell distribution width (RDW) also favors the diagnosis of HS. In unsplenectomized children, for example, elevations in MCHC (&gt;35",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [normal 31.1 to 34",
"    <span class=\"nowrap\">",
"     g/dL])",
"    </span>",
"    and RDW (&gt;14 [normal mean 12.6]) have a sensitivity of 63 percent and specificity of 100 percent for the diagnosis of HS, making these combined indices a powerful screening tool [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/15,25\">",
"     15,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480187\">",
"    <span class=\"h2\">",
"     Spherocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all cases of HS are initially suspected because spherocytes are found on the peripheral blood smear (",
"    <a class=\"graphic graphic_picture graphicRef70611 \" href=\"UTD.htm?27/1/27670\">",
"     picture 1",
"    </a>",
"    ). The degree of spherocytosis is a function of cell age as reticulocytes and young red cells are morphologically normal. The number of spherocytes seen on the peripheral smear varies with the severity of the defect. In the newborn and in mild cases in later life, spherocytes may be few in number (ie, one to three per high power field). In contrast, subjects with moderate disease may demonstrate 20 to 30 spherocytes per high power field.",
"   </p>",
"   <p>",
"    The morphology of the spherocytes is determined in part by the genetic defect. Variant spherocytic morphologies include notched or pincered spherocytes in band 3 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/26\">",
"     26",
"    </a>",
"    ], acanthocytic spherocytes in spectrin deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/27\">",
"     27",
"    </a>",
"    ] or dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/28\">",
"     28",
"    </a>",
"    ], dense and irregularly shaped cells in combined",
"    <span class=\"nowrap\">",
"     spectrin/ankyrin",
"    </span>",
"    deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/29\">",
"     29",
"    </a>",
"    ], and spherocytic elliptocytes in the disorder named spherocytic elliptocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9305?source=see_link\">",
"     \"Spiculated cells (echinocytes and acanthocytes) and target cells\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15623?source=see_link\">",
"     \"Hereditary elliptocytosis: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Acquired spherocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spherocytes are a feature of many hemolytic anemias; as a result, their identification on the peripheral blood smear is not sufficient to establish a diagnosis of HS. Spherocyte production is usually due to loss of membrane surface area in excess of loss of cell volume. There are several mechanisms by which membrane loss can occur in disorders other than HS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxidant injury in glucose-6-phosphate dehydrogenase deficiency or hemoglobin H disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=see_link\">",
"       \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Interaction of membrane-antibody complexes with the reticuloendothelial system leads to membrane loss through phagocytosis in autoimmune hemolytic anemias or alloimmune hemolytic anemia (eg, ABO incompatibility). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link\">",
"       \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Phospholipases or other membrane active enzymes in certain venoms and in clostridial sepsis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=see_link\">",
"       \"Extrinsic nonimmune hemolytic anemia due to systemic disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=see_link\">",
"       \"Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Erythrocyte fragmentation in mechanical hemolytic anemias (eg, microangiopathic hemolytic anemia). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link\">",
"       \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the exception of autoimmune and alloimmune hemolytic anemia, spherocytes are rarely the sole or dominant morphologic abnormality noted in these conditions. They also have easily recognized differences from HS in clinical course and laboratory tests that are specific for each disease. Macrospherocytes may be seen when red cell water content is increased and cell swelling occurs, as in hereditary hydrocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=see_link&amp;anchor=H7#H7\">",
"     \"Stomatocytosis\", section on 'Cryohydrocytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480380\">",
"    <span class=\"h2\">",
"     Pseudohyperkalemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A laboratory artifact that may be detected on routine laboratory testing is pseudohyperkalemia because of a high rate of potassium leakage out of the red cells as the blood is cooled after blood drawing [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/31\">",
"     31",
"    </a>",
"    ]. These patients have no signs or symptoms of hyperkalemia; rapid separation of the red cells from plasma will reveal a normal plasma potassium concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link&amp;anchor=H4#H4\">",
"     \"Causes and evaluation of hyperkalemia in adults\", section on 'Pseudohyperkalemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480294\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HS is almost always made on clinical grounds, based upon the presence of spherocytes (",
"    <a class=\"graphic graphic_picture graphicRef70611 \" href=\"UTD.htm?27/1/27670\">",
"     picture 1",
"    </a>",
"    ) in the setting of familial hemolytic anemia and an abnormal osmotic fragility test (",
"    <a class=\"graphic graphic_figure graphicRef69042 \" href=\"UTD.htm?11/48/12047\">",
"     figure 1",
"    </a>",
"    ) or other screening test (see below).",
"   </p>",
"   <p>",
"    Analysis of the specific membrane protein molecular defect responsible for HS in individual families is limited to specialized research facilities, and is based, at least in part, on results obtained with sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) of red cell membrane proteins. In any event, determination of the specific protein abnormality is of limited clinical utility [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=see_link&amp;anchor=H5#H5\">",
"     \"Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis\", section on 'Molecular pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Specific diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of tests are available for identifying individuals with HS. Some of the most commonly used tests are listed below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480428\">",
"    <span class=\"h3\">",
"     Osmotic fragility testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red cells behave as osmometers when suspended in buffered salt solutions of varying tonicities. The reduced surface area to volume ratio that is characteristic of spherocytes increases their susceptibility to osmotic lysis in hypotonic solutions. This is the basis for the classic fresh osmotic fragility test, which detects hemolysis by measuring the fraction of total hemoglobin released from red cells at progressively more dilute salt concentrations. The test detects hemolysis in circulating spherocytes at salt concentrations that do not affect normal or young red cells.",
"   </p>",
"   <p>",
"    However, in one series, the osmotic fragility test was normal in 34 percent of HS samples [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/24\">",
"     24",
"    </a>",
"    ]. The normal samples are those in which cell dehydration has reduced cell volume to a degree equivalent to the reduction in surface area. Incubation of blood specimens for 24 hours in the absence of metabolic substrate accentuates the osmotic fragility of spherocytes and makes it easier to distinguish HS from other diseases (",
"    <a class=\"graphic graphic_figure graphicRef69042 \" href=\"UTD.htm?11/48/12047\">",
"     figure 1",
"    </a>",
"    ). However, even after incubation, 15 percent of the samples in the above study had normal osmotic fragility [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/24\">",
"     24",
"    </a>",
"    ]. For this reason, attention has turned to other screening tests with greater sensitivity and specificity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480435\">",
"    <span class=\"h3\">",
"     Ektacytometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osmotic gradient ektacytometry, although not widely available, is a more accurate way to distinguish hereditary spherocytes from normal red cells. This methodology measures surface area to volume relationships as well as cell hydration and intrinsic membrane effects on deformability [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480442\">",
"    <span class=\"h3\">",
"     Acidified glycerol lysis test",
"    </span>",
"    &nbsp;&mdash;&nbsp;A simple screening test, the acidified glycerol lysis test (AGLT), in its most recently modified version appears to have greater sensitivity and selectivity than the osmotic fragility test [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/2,33\">",
"     2,33",
"    </a>",
"    ]. A variant of the glycerol lysis test, the Pink test, may have equivalent accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480449\">",
"    <span class=\"h3\">",
"     Cryohemolysis test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another approach to the diagnosis of HS is the cryohemolysis test, in which red cells are suspended in a hypertonic solution, briefly heated to 37&ordm;C, then cooled to 4&ordm;C for 10 minutes. Ease of performance and the wide separation in degree of hemolysis between spherocytes and normal cells are two attractive features of this test [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study compared cryohemolysis to two parameters of the osmotic fragility test: the salt concentration that caused 50 percent hemolysis; and the percent lysis at a constant salt concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/36\">",
"     36",
"    </a>",
"    ]. The cryohemolysis test was the only test that identified all cases, including asymptomatic disease carriers. The ability of this test to identify less severe cases probably reflects the dependence of cryohemolysis on factors that are more related to the primary membrane defects than to the surface area to volume ratio.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480456\">",
"    <span class=\"h3\">",
"     Eosin-5-maleimide binding test",
"    </span>",
"    &nbsp;&mdash;&nbsp;A flow cytometric test based on interaction between the dye eosin-5-maleimide and band 3 protein has been proposed (EMA binding test) as a rapid diagnostic test for HS, with reported sensitivity and specificity of 89 to 96 and 94 to 99 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Only small volumes of red cells are required (5 to 10 microL), the test can be performed on capillary blood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/40\">",
"     40",
"    </a>",
"    ], and results are available in two hours, suggesting its value in the newborn.",
"   </p>",
"   <p>",
"    Eosin-5-maleimide binds to several red cell proteins, including band 3, Rh polypeptides, and CD 47. Reduction in the amount of one or more of these membrane proteins in several forms of hereditary spherocytosis (eg, spectrin deficiency, band 3 deficiency) accounts for the high predictive value of this screening test [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/41\">",
"     41",
"    </a>",
"    ]. The value of this screening test for hereditary spherocytosis in a clinical setting has been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/33,42,43\">",
"     33,42,43",
"    </a>",
"    ]. Mild cases of hereditary spherocytosis may not always be detected, and false positive results may be obtained in congenital dyserythropoietic anemia type II [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/33\">",
"     33",
"    </a>",
"    ] and occasionally in autoimmune hemolytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24744963\">",
"    <span class=\"h2\">",
"     Use of multiple tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the sensitivity of most of the available tests for diagnosing HS is quite variable, and no one test reliably identifies all individuals with HS. The utility of the various tests, alone or in combination, was therefore evaluated in a series of 150 patients with HS. Results included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The sensitivity of the osmotic fragility test was 68 and 81 percent on fresh and incubated blood, respectively.",
"     </li>",
"     <li>",
"      The EMA binding test had sensitivities and specificities of 93 and 98 percent, respectively.",
"     </li>",
"     <li>",
"      The AGLT and Pink tests had sensitivities and specificities of 95 and 91 percent, respectively.",
"     </li>",
"     <li>",
"      A combination of the EMA binding test and AGLT enabled all patients with HS to be identified.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480232\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal alloimmune and acquired autoimmune hemolytic anemia are the conditions that most closely resemble HS morphologically. The latter can be distinguished from HS by the absence of a family history of hemolytic anemia, the presence of a positive direct antiglobulin (Coombs) test or other manifestations of autoimmune disease, and a relative lack of exacerbation of hemolysis in the incubated osmotic fragility test.",
"   </p>",
"   <p>",
"    In the newborn, ABO incompatibility is excluded by blood grouping of the mother and infant and by negative antiglobulin testing of newborn red cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=see_link&amp;anchor=H14#H14\">",
"     \"Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues\", section on 'ABO-induced disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480821\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with most congenital hemolytic anemias, no specific treatment for the underlying red cell defect is available. Supportive care consists of the following:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8117130\">",
"    <span class=\"h3\">",
"     Folic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    is generally given to subjects with severe degrees of hemolytic anemia (eg, paroxysmal nocturnal hemoglobinuria, sickle cell disease, glucose-6-phosphate dehydrogenase deficiency) because of increased needs for folic acid when hematopoiesis is markedly increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link&amp;anchor=H19#H19\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\", section on 'Increased requirements'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Megaloblastic anemia due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiency has been described in some subjects with severe HS, but there is no evidence that it is needed in those with mild degrees of hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/9\">",
"     9",
"    </a>",
"    ]. Suggested doses for those with severe hemolysis or those with HS of any degree of severity who are pregnant have been in the range of 1 to 5",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8117137\">",
"    <span class=\"h3\">",
"     Blood transfusion and erythropoietin",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that transfusion dependence is present in 70 to 80 percent of HS-affected infants during their first year of life, due to an inability of their bone marrow to adequately compensate for the need for increased red cell production [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/14,44\">",
"     14,44",
"    </a>",
"    ]. After this period, less than 30 percent require regular transfusion support. In one study, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    (EPO, 1000 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per week) with iron supplementation obviated the need for transfusion in 13 of 16 infants with severe HS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/44\">",
"     44",
"    </a>",
"    ]. As the infants grew and began to mount an adequate erythropoietic response, the EPO dose could be tapered and discontinued before the age of nine months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H948829\">",
"    <span class=\"h3\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (HCT) was successfully employed in the treatment of a Chinese woman who had both hereditary spherocytosis and chronic myeloid leukemia. Both diseases were cured [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/45\">",
"     45",
"    </a>",
"    ]. However, the risks of HCT outweigh the benefits for patients with isolated hereditary spherocytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Splenectomy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480814\">",
"    <span class=\"h3\">",
"     Operative splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The &ldquo;traditional&rdquo; approach to splenectomy has been total splenectomy via laparotomy. A search is made for accessory splenic tissue, which, if not removed, may grow and result in the recurrence of symptomatic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/46\">",
"     46",
"    </a>",
"    ]. Immediate risks of operative splenectomy, which include hemorrhage at the operative site, postoperative infection, or injury to adjacent organs (eg, stomach, tail of the pancreas), are those associated with any surgical procedure and are relatively infrequent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480807\">",
"    <span class=\"h3\">",
"     Laparoscopic splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although operative splenectomy (OS) has not been directly compared with laparoscopic splenectomy (LS) in a randomized trial, the latter is preferred to OS in many centers, particularly in children, since, in comparison with historical controls, it appears to shorten hospitalization, and reduces operative time and postoperative pain, although operative bleeding may not be reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. As an example, in a case control study of 82 consecutive children and adolescents undergoing splenectomy for hematologic disorders (43 with HS), estimated blood loss was similar (54 versus 49 mL), while operative time (83 versus 115 minutes), need for postoperative intravenous narcotics (51 versus 100 percent), and hospital length of stay (1.4 versus 2.5 days) were all significantly less with LS as compared with OS.",
"   </p>",
"   <p>",
"    It may be necessary to extend the incision, particularly when the spleen is enlarged. Splenic artery embolization, performed one day prior to laparoscopic splenectomy, diminished intraoperative blood loss and was free of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/51\">",
"     51",
"    </a>",
"    ]. All patients reported postembolic pain, which could be controlled by the use of intravascular narcotics.",
"   </p>",
"   <p>",
"    A potential problem with laparoscopic splenectomy is incomplete eradication of splenic tissue, since there is limited ability to detect and remove accessory spleens, which may be located at distant sites within the abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In one study of 18 patients treated by elective laparoscopic splenectomy for hematologic diseases, 16 accessory spleens were detected in seven patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/53\">",
"     53",
"    </a>",
"    ]. Laparoscopic exploration failed to detect accessory spleens in two patients, and nine patients showed persistence of splenic tissue by denatured red blood cell scintigraphy at a mean follow-up of 28 months. Three of these nine patients had signs of recurrent hemolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480669\">",
"    <span class=\"h3\">",
"     Partial splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The higher risk of overwhelming sepsis in young children who undergo total splenectomy makes it important to defer the operation until at least age six in all but the most severely affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/9\">",
"     9",
"    </a>",
"    ]. For young children who need immediate splenectomy because of frequent transfusions, the use of partial splenectomy has been evaluated in an attempt to preserve the immunologic functions of the spleen while reducing the degree of splenic entrapment and destruction of spherocytic red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/54-59\">",
"     54-59",
"    </a>",
"    ]. Partial splenectomy has also been accomplished via a laparoscopic approach [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/59,60\">",
"     59,60",
"    </a>",
"    ] and by robotic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Removal of 80 to 90 percent of the spleen reduces hemolysis, but not to the extent seen following complete splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/59\">",
"     59",
"    </a>",
"    ]. There are proponents for preserving the lower pole of the spleen [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/62\">",
"     62",
"    </a>",
"    ] as well as those favoring preservation of the upper pole [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/58\">",
"     58",
"    </a>",
"    ], mostly on technical grounds. Similarly, partial splenectomy can be performed using an open or a laparoscopic approach; the choice usually depends upon the experience and preference of the surgeon.",
"   </p>",
"   <p>",
"    Following partial splenectomy, the phagocytic function of the spleen, assessed by red cell pit counts",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    splenic uptake of radiolabeled, heat-treated red cells, is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/59\">",
"     59",
"    </a>",
"    ] and, in more than 40 patients with HS followed for up to 14 years in one series, there have been no episodes of serious or fatal sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/54,63\">",
"     54,63",
"    </a>",
"    ]. However, mild-to-moderate hemolysis was persistent and accounted for secondary gallstone formation and aplastic crisis in a small subset of patients.owever, milH",
"   </p>",
"   <p>",
"    The spleen eventually regains its previous size and a second (complete) splenectomy will probably be required in most patients, at a time when they are considerably older, with a reduced risk of sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480676\">",
"    <span class=\"h3\">",
"     Near total splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic remnant regrowth may be less when near total splenectomy is performed. One study reported on 31 patients with HS, in whom 98 percent of the spleen had been surgically removed (range: 93 to 99 percent), with a splenic remnant of approximately 10 cubic centimeters (range 6 to 12 cubic centimeters) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/56\">",
"     56",
"    </a>",
"    ]. At a median follow-up of 3.6 years, mean splenic remnant size was 63, 71, and 28 cubic centimeters for those with mild, moderate, or severe degrees of preoperative anemia, respectively, while mean postoperative hemoglobin levels were 14.8, 12.8, and 12.6",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    respectively. Secondary intervention for newly developed cholelithiasis was performed in two patients; one four-year-old child with severe HS developed necrosis of the splenic remnant. It remains unclear whether the very small remnant of splenic tissue provides any immunological protection against overwhelming sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy eliminates or minimizes anemia in patients with moderate spherocytosis (",
"    <a class=\"graphic graphic_table graphicRef54945 \" href=\"UTD.htm?1/50/1836\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/6,24,64\">",
"     6,24,64",
"    </a>",
"    ]. The elevated serum bilirubin concentration and reticulocytosis fall within several days to high normal levels. The hemoglobin concentration rises, although red cell survival remains shortened.",
"   </p>",
"   <p>",
"    In severely affected patients, life-threatening anemia and a need for regular transfusions are abolished by splenectomy, although a moderate degree of anemia usually persists [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/65\">",
"     65",
"    </a>",
"    ]. Splenectomy prior to the formation of bilirubin gallstones can also eliminate the need for cholecystectomy later in life.",
"   </p>",
"   <p>",
"    Growth failure or skeletal changes due to the high degree of erythropoiesis need to compensate for severe hemolytic anemia will be reversed or ameliorated by splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of splenectomy must be balanced against the immediate and long term risks of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480793\">",
"    <span class=\"h4\">",
"     Sepsis with encapsulated bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most feared complication of splenectomy is the possibility of developing overwhelming sepsis with encapsulated bacteria, most commonly Streptococcus pneumoniae. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=see_link\">",
"     \"Clinical features and management of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A literature review in 1973 evaluated 850 patients, mostly infants and children, who had undergone splenectomy for HS: 3.5 percent developed sepsis and 2.2 percent died of infection [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 1995 retrospective review evaluated 226 patients with HS who underwent splenectomy up to 45 years earlier [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/67\">",
"       67",
"      </a>",
"      ]. The four deaths from sepsis occurred 2, 18, 23, and 30 years after splenectomy, and the estimated mortality from overwhelming sepsis was 0.73 per 1000 patient years. The mortality rates for the 35 children who underwent splenectomy prior to six years of age and for the 191 individuals who underwent splenectomy at an older age were 1.12 and 0.66 per 1000 years, respectively after splenectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/67\">",
"       67",
"      </a>",
"      ]. These rates were far higher than those seen in the general population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The complication rates in these two studies probably overestimate the risk of sepsis for contemporary patients, since most of the participants underwent splenectomy prior to the introduction of the pneumococcal vaccine and the routine use of antibiotics in patients with fever. The effectiveness of pneumococcal vaccination and antibiotic prophylaxis in splenectomized children was documented in a Danish study [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/68\">",
"     68",
"    </a>",
"    ]. The study compared rates of either meningitis or bacteremia due to Streptococcus pneumoniae during the period 1969 to 1978 when the vaccine was not available to rates of infection during the period 1979 to 1987. Invasive pneumococcal infection occurred in 4 percent of the children splenectomized during the earlier time period versus none of the children splenectomized and vaccinated during the later period. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Recommendations for or against splenectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Splenectomy may pose special infectious risks for individuals living in geographic regions where parasitic diseases such as malaria or babesiosis occur [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8117348\">",
"    <span class=\"h4\">",
"     Optimum age for splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies that establish the &ldquo;optimal&rdquo; time for splenectomy, although it has been suggested that splenectomy be performed as late as possible, preferably after the age of six years, and not before the age of three years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/1\">",
"     1",
"    </a>",
"    ]. Available data on this issue include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective review of 226 patients with HS who underwent splenectomy, the mortality rates for the 35 children who underwent splenectomy prior to six years of age and for the 191 individuals who underwent splenectomy at an older age were 1.12 and 0.66 per 1000 years, respectively, after splenectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective review of all children who had splenectomy at a single medical center, 10 of the 264 patients (3.8 percent) developed post-splenectomy sepsis within a mean period of two years [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/71\">",
"       71",
"      </a>",
"      ]. Nine of the 10 episodes occurred in patients who had undergone splenectomy between the ages of zero and five years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Arterial and venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is reason for some concern about post-splenectomy leukocytosis and thrombocytosis, since both arterial and venous thromboembolic events have been reported in patients splenectomized for HS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/72,73\">",
"     72,73",
"    </a>",
"    ], other hereditary hemolytic anemias [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/74,75\">",
"     74,75",
"    </a>",
"    ], or trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/76\">",
"     76",
"    </a>",
"    ]. One report documents that increased hemoglobin, white blood cell count, platelet count, and fibrinogen level, all features that may increase thrombotic risk, are laboratory findings characteristically seen after splenectomy for hereditary spherocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 232 patients with HS, evidence for arteriosclerosis after the age of 40 (stroke, myocardial infarction, coronary or carotid surgery) was six times greater in the 144 patients who were splenectomized than in the 88 subjects who did not have this operation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second report, based upon answers to a questionnaire, subjects with HS who underwent splenectomy had a greatly increased life-long cumulative risk of arterial (HR 7.2; 95% CI 2.8-17) and venous (HR 3.3; 95% CI 1.1-9.8) thromboembolic events as compared with subjects with HS who did not undergo this operation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/79\">",
"       79",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      When splenectomized HS patients were compared with unaffected relatives, the differences were similar but less striking. A provocative finding of this report was that non-splenectomized HS subjects had far fewer thromboembolic events than their relatives who did not have HS. This apparent protective effect of HS pre-splenectomy may relate to the presence of anemia, high bilirubin levels,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      low cholesterol, all factors reported to be characteristic of non-splenectomized HS patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Isolated case reports of splenic infarction in HS patients who also had sickle cell trait [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/80\">",
"     80",
"    </a>",
"    ] or were infected with Epstein Barr virus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/81,82\">",
"     81,82",
"    </a>",
"    ], as well as HS patients who developed pulmonary thromboembolism or pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/73,83-85\">",
"     73,83-85",
"    </a>",
"    ] have also raised concern about a possible connection between HS and thrombotic risk. However, no studies have addressed the use of extended thromboprophylaxis in this setting, and no recommendations regarding treatment can be made at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Recommendations for or against splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding splenectomy must take into account the severity of hemolysis, age of the patient, and the various associated risks (see above) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/64\">",
"     64",
"    </a>",
"    ]. A consensus perspective on the relative risks and benefits of splenectomy in the setting of hereditary spherocytosis was published in 2004 by the General Haematology Task Force of the British Committee for Standards in Haematology [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mild or asymptomatic disease",
"      </strong>",
"      &mdash; In mild HS, the purpose of splenectomy is solely to prevent gallstone formation. In this setting (ie, mild HS and no gallstones), the risks of the procedure appear to exceed those associated with expectant management in a decision analysis model based upon the available literature and computer modelling [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/86,87\">",
"       86,87",
"      </a>",
"      ]. However, this analysis concluded that combined prophylactic splenectomy and cholecystectomy provided a substantial gain in quality-adjusted life expectancy for patients with mild HS under the age of 39 who had asymptomatic gallstones and for patients under the age of 52 with gallstones accompanied by occasional episodes of biliary colic [",
"      <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/87\">",
"       87",
"      </a>",
"      ]. However, this model was extremely sensitive to compliance with post-splenectomy infection prophylaxis.",
"     </li>",
"     <li>",
"      <strong>",
"       Moderate, symptomatic disease",
"      </strong>",
"      &mdash; When hemolysis and anemia are more severe and symptomatic, splenectomy with pneumococcal vaccine and oral antibiotic prophylaxis as described above are warranted. At present, the optimal strategy includes administration of anti-pneumococcal, Haemophilus, and meningococcal vaccines several weeks before the operation and daily oral penicillin prophylaxis (125 mg penicillin twice daily for children under three years and 250 mg twice daily for older individuals). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"       \"Prevention of sepsis in the asplenic patient\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to remeasure antibody levels five years after vaccination, as antibody levels will have decreased in a significant number of patients to such an extent that revaccination is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Patients who have undergone total or near total splenectomy remain capable of responding to both the 23-valent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/89\">",
"     89",
"    </a>",
"    ]. Young children should also receive H. Influenza immunization before splenectomy.",
"   </p>",
"   <p>",
"    In view of reported deaths from sepsis up to 30 years or more after splenectomy, a case can be made for lifetime penicillin prophylaxis. As an alternative, a supply of antibiotics can be made available to the patient for",
"    <strong>",
"     immediate",
"    </strong>",
"    treatment of any significant fever at home. The emerging risk of penicillin-resistant pneumococcal infections requires vigilance and prompt selection of alternative antibiotics in hospitalized patients who have documented pneumococcal sepsis and remain febrile despite intravenous antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subtotal splenectomy should be accompanied by all of the precautions regarding potential sepsis risk, in case of secondary necrosis of the splenic remnant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/63\">",
"     63",
"    </a>",
"    ]. This includes the appropriate vaccinations presurgery (see above), and oral penicillin prophylaxis post-surgery. The latter can be discontinued only if normal phagocytic function of the splenic remnant has been documented.",
"   </p>",
"   <p>",
"    In patients for whom splenectomy is appropriate but surgery is refused or contraindicated, partial splenic embolization has been employed, with anecdotal reports of success [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480873\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15480888\">",
"    <span class=\"h2\">",
"     Suspecting the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hereditary spherocytosis (HS) is suspected in the presence of anemia, jaundice, and splenomegaly in a subject with a positive family history of hemolytic anemia.",
"   </p>",
"   <p>",
"    Routine blood counts reveal anemia and reticulocytosis, a low mean corpuscular volume (MCV), increased mean corpuscular hemoglobin concentration (MCHC), and an increased red cell distribution width (RDW). Spherocytes are prominent on the peripheral blood smear. Direct and indirect antiglobulin tests are negative. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Laboratory studies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14834872\">",
"    <span class=\"h2\">",
"     Disorders that may be confused with HS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The two major conditions that may be confused with HS are alloimmune and autoimmune hemolytic anemia. Both are associated with a positive antiglobulin (Coombs) test, a test that is negative in HS. (See",
"      <a class=\"local\" href=\"#H15480232\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Spherocytes may be seen in other conditions (eg, glucose-6-phosphate (G6PD) deficiency, clostridial sepsis, snake bite, microangiopathic hemolytic anemia), but the clinical setting and laboratory findings are significantly different from those in HS. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Acquired spherocytosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14834763\">",
"    <span class=\"h2\">",
"     Confirming the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HS is confirmed in the presence of an abnormal screening test. The classic osmotic fragility test (",
"    <a class=\"graphic graphic_figure graphicRef69042 \" href=\"UTD.htm?11/48/12047\">",
"     figure 1",
"    </a>",
"    ) has been supplanted by the more accurate eosin-5-maleimide binding test either alone or in combination with a second test, such as the acidified glycerol lysis time [",
"    <a class=\"abstract\" href=\"UTD.htm?20/1/20506/abstract/33\">",
"     33",
"    </a>",
"    ] or the cryohemolysis test. (See",
"    <a class=\"local\" href=\"#H24744963\">",
"     'Use of multiple tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Analysis of the specific membrane protein molecular defects responsible for HS in individual families is limited to specialized research facilities and does not generally affect treatment. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Specific diagnostic tests'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14834937\">",
"    <span class=\"h2\">",
"     Management of anemia",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Red cell transfusions should be given for those with symptomatic anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18808?source=see_link&amp;anchor=H7#H7\">",
"       \"Indications for red blood cell transfusion in infants and children\", section on 'Chronic anemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"       \"Indications for red cell transfusion in the adult\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest the use of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      to support increased erythropoiesis and prevent folic acid deficiency in those with severe HS (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8117130\">",
"       'Folic acid'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14834944\">",
"    <span class=\"h2\">",
"     Consideration of splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consideration for elective splenectomy with or without cholecystectomy is an important part of the management of the patient with HS. While there have been no randomized trials concerning the type of procedure (eg, operative, laparoscopic), the extent of surgery (eg, complete, partial, near total), nor the age at which the procedure should be performed, the following general principles apply:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risks and benefits of splenectomy must be discussed with, and understood by, the patient and family. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Benefits'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Splenectomy prior to the formation of bilirubin gallstones can eliminate the need for cholecystectomy later in life.",
"     </li>",
"     <li>",
"      Where possible, we suggest laparoscopic splenectomy rather than operative splenectomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Limited evidence suggests that laparoscopic splenectomy shortens hospitalization and reduces postoperative pain when compared with operative splenectomy. (See",
"      <a class=\"local\" href=\"#H15480807\">",
"       'Laparoscopic splenectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Where possible, we suggest that splenectomy be deferred until at least age six, rather than at an earlier age (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This is due to the higher risk of overwhelming sepsis in young children who undergo splenectomy. (See",
"      <a class=\"local\" href=\"#H8117348\">",
"       'Optimum age for splenectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not performing splenectomy in patients with mild HS (ie, hemolysis without anemia) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Recommendations for or against splenectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients who have been splenectomized are at risk for sepsis with encapsulated organisms. Recommendations for immunization prior to splenectomy and antibiotic prophylaxis following splenectomy are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link&amp;anchor=H17#H17\">",
"       \"Prevention of sepsis in the asplenic patient\", section on 'Prevention of postsplenectomy sepsis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/1\">",
"      Bolton-Maggs PH, Langer JC, Iolascon A, et al. Guidelines for the diagnosis and management of hereditary spherocytosis--2011 update. Br J Haematol 2012; 156:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/2\">",
"      Eber SW, Pekrun A, Neufeldt A, Schr&ouml;ter W. Prevalence of increased osmotic fragility of erythrocytes in German blood donors: screening using a modified glycerol lysis test. Ann Hematol 1992; 64:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/3\">",
"      Randon J, Miraglia del Giudice E, Bozon M, et al. Frequent de novo mutations of the ANK1 gene mimic a recessive mode of transmission in hereditary spherocytosis: three new ANK1 variants: ankyrins Bari, Napoli II and Anzio. Br J Haematol 1997; 96:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/4\">",
"      Miraglia del Giudice E, Francese M, Nobili B, et al. High frequency of de novo mutations in ankyrin gene (ANK1) in children with hereditary spherocytosis. J Pediatr 1998; 132:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/5\">",
"      Miraglia del Giudice E, Lombardi C, Francese M, et al. Frequent de novo monoallelic expression of beta-spectrin gene (SPTB) in children with hereditary spherocytosis and isolated spectrin deficiency. Br J Haematol 1998; 101:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/6\">",
"      Eber SW, Armbrust R, Schr&ouml;ter W. Variable clinical severity of hereditary spherocytosis: relation to erythrocytic spectrin concentration, osmotic fragility, and autohemolysis. J Pediatr 1990; 117:409.",
"     </a>",
"    </li>",
"    <li>",
"     Lux SE, Palek J. Disorders of the red cell membrane. In: Blood. Principles and Practice of Hematology, Handin RI, Lux SE, Stossel TP (Eds), Lippincott, Philadelphia 1995. p.1701.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/8\">",
"      Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet 2008; 372:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/9\">",
"      Bolton-Maggs PH, Stevens RF, Dodd NJ, et al. Guidelines for the diagnosis and management of hereditary spherocytosis. Br J Haematol 2004; 126:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/10\">",
"      Rocha S, Costa E, Catarino C, et al. Erythropoietin levels in the different clinical forms of hereditary spherocytosis. Br J Haematol 2005; 131:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/11\">",
"      Guarnone R, Centenara E, Zappa M, et al. Erythropoietin production and erythropoiesis in compensated and anaemic states of hereditary spherocytosis. Br J Haematol 1996; 92:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/12\">",
"      Whitfield CF, Follweiler JB, Lopresti-Morrow L, Miller BA. Deficiency of alpha-spectrin synthesis in burst-forming units-erythroid in lethal hereditary spherocytosis. Blood 1991; 78:3043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/13\">",
"      Schr&ouml;ter W, Kahsnitz E. Diagnosis of hereditary spherocytosis in newborn infants. J Pediatr 1983; 103:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/14\">",
"      Delhommeau F, Cynober T, Schischmanoff PO, et al. Natural history of hereditary spherocytosis during the first year of life. Blood 2000; 95:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/15\">",
"      Christensen RD, Henry E. Hereditary spherocytosis in neonates with hyperbilirubinemia. Pediatrics 2010; 125:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/16\">",
"      MACKINNEY AA Jr. HEREDITARY SPHEROCYTOSIS; CLINICAL FAMILY STUDIES. Arch Intern Med 1965; 116:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/17\">",
"      BATES GC, BROWN CH. Incidence of gallbladder disease in chronic hemolytic anemia (spherocytosis). Gastroenterology 1952; 21:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/18\">",
"      Cooper RA, Jandl JH. The role of membrane lipids in the survival of red cells in hereditary spherocytosis. J Clin Invest 1969; 48:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/19\">",
"      del Giudice EM, Perrotta S, Nobili B, et al. Coinheritance of Gilbert syndrome increases the risk for developing gallstones in patients with hereditary spherocytosis. Blood 1999; 94:2259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/20\">",
"      Rabhi S, Benjelloune H, Meziane M, et al. Hereditary spherocytosis with leg ulcers healing after splenectomy. South Med J 2011; 104:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/21\">",
"      Bastion Y, Coiffier B, Felman P, et al. Massive mediastinal extramedullary hematopoiesis in hereditary spherocytosis: a case report. Am J Hematol 1990; 35:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/22\">",
"      Smith J, Rahilly M, Davidson K. Extramedullary haematopoiesis secondary to hereditary spherocytosis. Br J Haematol 2011; 154:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/23\">",
"      Prabhakaran K, Jacobs BL, Smaldone MC, Franks ME. Stuttering priapism associated with hereditary spherocytosis. Can J Urol 2007; 14:3702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/24\">",
"      Cynober T, Mohandas N, Tchernia G. Red cell abnormalities in hereditary spherocytosis: relevance to diagnosis and understanding of the variable expression of clinical severity. J Lab Clin Med 1996; 128:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/25\">",
"      Michaels LA, Cohen AR, Zhao H, et al. Screening for hereditary spherocytosis by use of automated erythrocyte indexes. J Pediatr 1997; 130:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/26\">",
"      Jarolim P, Murray JL, Rubin HL, et al. Characterization of 13 novel band 3 gene defects in hereditary spherocytosis with band 3 deficiency. Blood 1996; 88:4366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/27\">",
"      Hassoun H, Vassiliadis JN, Murray J, et al. Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency. Blood 1997; 90:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/28\">",
"      Becker PS, Tse WT, Lux SE, Forget BG. Beta spectrin kissimmee: a spectrin variant associated with autosomal dominant hereditary spherocytosis and defective binding to protein 4.1. J Clin Invest 1993; 92:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/29\">",
"      Coetzer TL, Lawler J, Liu SC, et al. Partial ankyrin and spectrin deficiency in severe, atypical hereditary spherocytosis. N Engl J Med 1988; 318:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/30\">",
"      Palek J, Jarolim P. Clinical expression and laboratory detection of red blood cell membrane protein mutations. Semin Hematol 1993; 30:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/31\">",
"      Alani FS, Dyer T, Hindle E, et al. Pseudohyperkalaemia associated with hereditary spherocytosis in four members of a family. Postgrad Med J 1994; 70:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/32\">",
"      Mariani M, Barcellini W, Vercellati C, et al. Clinical and hematologic features of 300 patients affected by hereditary spherocytosis grouped according to the type of the membrane protein defect. Haematologica 2008; 93:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/33\">",
"      Bianchi P, Fermo E, Vercellati C, et al. Diagnostic power of laboratory tests for hereditary spherocytosis: a comparison study in 150 patients grouped according to molecular and clinical characteristics. Haematologica 2012; 97:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/34\">",
"      Bucx MJ, Breed WP, Hoffmann JJ. Comparison of acidified glycerol lysis test, Pink test and osmotic fragility test in hereditary spherocytosis: effect of incubation. Eur J Haematol 1988; 40:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/35\">",
"      Romero RR, Poo JL, Robles JA, et al. Usefulness of cryohemolysis test in the diagnosis of hereditary spherocytosis. Arch Med Res 1997; 28:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/36\">",
"      Streichman S, Gescheidt Y. Cryohemolysis for the detection of hereditary spherocytosis: correlation studies with osmotic fragility and autohemolysis. Am J Hematol 1998; 58:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/37\">",
"      King MJ, Behrens J, Rogers C, et al. Rapid flow cytometric test for the diagnosis of membrane cytoskeleton-associated haemolytic anaemia. Br J Haematol 2000; 111:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/38\">",
"      Girodon F, Gar&ccedil;on L, Bergoin E, et al. Usefulness of the eosin-5'-maleimide cytometric method as a first-line screening test for the diagnosis of hereditary spherocytosis: comparison with ektacytometry and protein electrophoresis. Br J Haematol 2008; 140:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/39\">",
"      Kar R, Mishra P, Pati HP. Evaluation of eosin-5-maleimide flow cytometric test in diagnosis of hereditary spherocytosis. Int J Lab Hematol 2010; 32:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/40\">",
"      Crisp RL, Solari L, Gammella D, et al. Use of capillary blood to diagnose hereditary spherocytosis. Pediatr Blood Cancer 2012; 59:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/41\">",
"      King MJ, Smythe JS, Mushens R. Eosin-5-maleimide binding to band 3 and Rh-related proteins forms the basis of a screening test for hereditary spherocytosis. Br J Haematol 2004; 124:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/42\">",
"      Stoya G, Gruhn B, Vogelsang H, et al. Flow cytometry as a diagnostic tool for hereditary spherocytosis. Acta Haematol 2006; 116:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/43\">",
"      Crisp RL, Solari L, Vota D, et al. A prospective study to assess the predictive value for hereditary spherocytosis using five laboratory tests (cryohemolysis test, eosin-5'-maleimide flow cytometry, osmotic fragility test, autohemolysis test, and SDS-PAGE) on 50 hereditary spherocytosis families in Argentina. Ann Hematol 2011; 90:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/44\">",
"      Tchernia G, Delhommeau F, Perrotta S, et al. Recombinant erythropoietin therapy as an alternative to blood transfusions in infants with hereditary spherocytosis. Hematol J 2000; 1:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/45\">",
"      Zhang XH, Fu HX, Xu LP, et al. Allo-hematopoietic stem cell transplantation is a potential treatment for a patient with a combined disorder of hereditary spherocytosis. Chin Med J (Engl) 2012; 125:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/46\">",
"      MACKENZIE AE, ELLIOT DH, EASTCOTT HH, et al. Relapse in hereditary spherocytosis with proven splenunculus. Lancet 1962; 1:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/47\">",
"      Curran TJ, Foley MI, Swanstrom LL, Campbell TJ. Laparoscopy improves outcomes for pediatric splenectomy. J Pediatr Surg 1998; 33:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/48\">",
"      Rescorla FJ, Breitfeld PP, West KW, et al. A case controlled comparison of open and laparoscopic splenectomy in children. Surgery 1998; 124:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/49\">",
"      Holcomb GW 3rd. Laparoscopic cholecystectomy. Semin Laparosc Surg 1998; 5:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/50\">",
"      Tanoue K, Okita K, Akahoshi T, et al. Laparoscopic splenectomy for hematologic diseases. Surgery 2002; 131:S318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/51\">",
"      Takahashi T, Arima Y, Yokomuro S, et al. Splenic artery embolization before laparoscopic splenectomy in children. Surg Endosc 2005; 19:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/52\">",
"      Gigot JF, Lengele B, Gianello P, et al. Present status of laparoscopic splenectomy for hematologic diseases: certitudes and unresolved issues. Semin Laparosc Surg 1998; 5:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/53\">",
"      Gigot JF, Jamar F, Ferrant A, et al. Inadequate detection of accessory spleens and splenosis with laparoscopic splenectomy. A shortcoming of the laparoscopic approach in hematologic diseases. Surg Endosc 1998; 12:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/54\">",
"      Tchernia G, Bader-Meunier B, Berterottiere P, et al. Effectiveness of partial splenectomy in hereditary spherocytosis. Curr Opin Hematol 1997; 4:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/55\">",
"      Stoehr GA, Stauffer UG, Eber SW. Near-total splenectomy: a new technique for the management of hereditary spherocytosis. Ann Surg 2005; 241:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/56\">",
"      Stoehr GA, Sobh JN, Luecken J, et al. Near-total splenectomy for hereditary spherocytosis: clinical prospects in relation to disease severity. Br J Haematol 2006; 132:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/57\">",
"      Dutta S, Price VE, Blanchette V, Langer JC. A laparoscopic approach to partial splenectomy for children with hereditary spherocytosis. Surg Endosc 2006; 20:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/58\">",
"      Tracy ET, Rice HE. Partial splenectomy for hereditary spherocytosis. Pediatr Clin North Am 2008; 55:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/59\">",
"      Buesing KL, Tracy ET, Kiernan C, et al. Partial splenectomy for hereditary spherocytosis: a multi-institutional review. J Pediatr Surg 2011; 46:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/60\">",
"      Morinis J, Dutta S, Blanchette V, et al. Laparoscopic partial vs total splenectomy in children with hereditary spherocytosis. J Pediatr Surg 2008; 43:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/61\">",
"      Vasilescu C, Stanciulea O, Tudor S. Laparoscopic versus robotic subtotal splenectomy in hereditary spherocytosis. Potential advantages and limits of an expensive approach. Surg Endosc 2012; 26:2802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/62\">",
"      Vasilescu C, Stanciulea O, Tudor S, et al. Laparoscopic subtotal splenectomy in hereditary spherocytosis : to preserve the upper or the lower pole of the spleen? Surg Endosc 2006; 20:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/63\">",
"      Bader-Meunier B, Gauthier F, Archambaud F, et al. Long-term evaluation of the beneficial effect of subtotal splenectomy for management of hereditary spherocytosis. Blood 2001; 97:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/64\">",
"      Schilling RF. Risks and benefits of splenectomy versus no splenectomy for hereditary spherocytosis--a personal view. Br J Haematol 2009; 145:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/65\">",
"      Agre P, Asimos A, Casella JF, McMillan C. Inheritance pattern and clinical response to splenectomy as a reflection of erythrocyte spectrin deficiency in hereditary spherocytosis. N Engl J Med 1986; 315:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/66\">",
"      Singer DB. Postsplenectomy sepsis. Perspect Pediatr Pathol 1973; 1:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/67\">",
"      Schilling RF. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med 1995; 122:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/68\">",
"      Konradsen HB, Henrichsen J. Pneumococcal infections in splenectomized children are preventable. Acta Paediatr Scand 1991; 80:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/69\">",
"      Persing DH, Herwaldt BL, Glaser C, et al. Infection with a babesia-like organism in northern California. N Engl J Med 1995; 332:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/70\">",
"      Herwaldt B, Persing DH, Pr&eacute;cigout EA, et al. A fatal case of babesiosis in Missouri: identification of another piroplasm that infects humans. Ann Intern Med 1996; 124:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/71\">",
"      Jugenburg M, Haddock G, Freedman MH, et al. The morbidity and mortality of pediatric splenectomy: does prophylaxis make a difference? J Pediatr Surg 1999; 34:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/72\">",
"      Verresen D, De Backer W, Van Meerbeeck J, et al. Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship? Eur Respir J 1991; 4:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/73\">",
"      Hayag-Barin JE, Smith RE, Tucker FC Jr. Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: a case report and review of the literature. Am J Hematol 1998; 57:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/74\">",
"      Stewart GW, Amess JA, Eber SW, et al. Thrombo-embolic disease after splenectomy for hereditary stomatocytosis. Br J Haematol 1996; 93:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/75\">",
"      Tso SC, Chan TK, Todd D. Venous thrombosis in haemoglobin H disease after splenectomy. Aust N Z J Med 1982; 12:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/76\">",
"      Robinette CD, Fraumeni JF Jr. Splenectomy and subsequent mortality in veterans of the 1939-45 war. Lancet 1977; 2:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/77\">",
"      Crary SE, Troendle S, Ahmad N, Buchanan GR. Traditional laboratory measures of cardiovascular risk in hereditary spherocytosis. Pediatr Blood Cancer 2010; 55:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/78\">",
"      Schilling RF. Spherocytosis, splenectomy, strokes, and heat attacks. Lancet 1997; 350:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/79\">",
"      Schilling RF, Gangnon RE, Traver MI. Delayed adverse vascular events after splenectomy in hereditary spherocytosis. J Thromb Haemost 2008; 6:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/80\">",
"      Dulman RY, Buchanan GR, Ginsburg H, et al. Splenic infarction due to concomitant hereditary spherocytosis and sickle cell trait. J Pediatr Surg 2007; 42:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/81\">",
"      Breuer C, Janssen G, Laws HJ, et al. Splenic infarction in a patient hereditary spherocytosis, protein C deficiency and acute infectious mononucleosis. Eur J Pediatr 2008; 167:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/82\">",
"      Suzuki Y, Shichishima T, Mukae M, et al. Splenic infarction after Epstein-Barr virus infection in a patient with hereditary spherocytosis. Int J Hematol 2007; 85:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/83\">",
"      Bhargava K, Chandra N, Omar AK, Mathur A. Protein C deficiency leading to pulmonary thromboembolism in a patient with hereditary spherocytosis. Indian Heart J 2006; 58:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/84\">",
"      Smedema JP, Louw VJ. Pulmonary arterial hypertension after splenectomy for hereditary spherocytosis. Cardiovasc J Afr 2007; 18:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/85\">",
"      Smedema JP, Abrahams S, Louw VJ. Partial reversal of hemolysis-associated pulmonary arterial hypertension in response to oral administration of L-arginine in a patient with hereditary spherocytosis. Acta Haematol 2007; 118:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/86\">",
"      Manno CS, Cohen AR. Splenectomy in mild hereditary spherocytosis: is it worth the risk? Am J Pediatr Hematol Oncol 1989; 11:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/87\">",
"      Marchetti M, Quaglini S, Barosi G. Prophylactic splenectomy and cholecystectomy in mild hereditary spherocytosis: analyzing the decision in different clinical scenarios. J Intern Med 1998; 244:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/88\">",
"      Konradsen HB, Rasmussen C, Ejstrud P, Hansen JB. Antibody levels against Streptococcus pneumoniae and Haemophilus influenzae type b in a population of splenectomized individuals with varying vaccination status. Epidemiol Infect 1997; 119:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/89\">",
"      Stoehr GA, Rose MA, Eber SW, et al. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis. Br J Haematol 2006; 132:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/90\">",
"      Wang WC, Wong WY, Rogers ZR, et al. Antibiotic-resistant pneumococcal infection in children with sickle cell disease in the United States. J Pediatr Hematol Oncol 1996; 18:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/1/20506/abstract/91\">",
"      Kimura F, Ito H, Shimizu H, et al. Partial splenic embolization for the treatment of hereditary spherocytosis. AJR Am J Roentgenol 2003; 181:1021.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7079 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-C1CDB4E621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_1_20506=[""].join("\n");
var outline_f20_1_20506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15480873\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15480082\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Signs and symptoms according to age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15480097\">",
"      - In utero",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15480104\">",
"      - Neonatal period",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15480111\">",
"      - Infancy and adulthood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gallstone formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15480142\">",
"      Other complications of HS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LABORATORY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15480173\">",
"      Complete blood count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15480180\">",
"      Red blood cell indices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14834620\">",
"      - Mean corpuscular volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14834613\">",
"      - Mean corpuscular hemoglobin concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15480187\">",
"      Spherocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Acquired spherocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15480380\">",
"      Pseudohyperkalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15480294\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Specific diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15480428\">",
"      - Osmotic fragility testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15480435\">",
"      - Ektacytometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15480442\">",
"      - Acidified glycerol lysis test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15480449\">",
"      - Cryohemolysis test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15480456\">",
"      - Eosin-5-maleimide binding test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24744963\">",
"      Use of multiple tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15480232\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15480821\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8117130\">",
"      - Folic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8117137\">",
"      - Blood transfusion and erythropoietin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H948829\">",
"      - Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15480814\">",
"      - Operative splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15480807\">",
"      - Laparoscopic splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15480669\">",
"      - Partial splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15480676\">",
"      - Near total splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Benefits",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15480793\">",
"      Sepsis with encapsulated bacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8117348\">",
"      Optimum age for splenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Arterial and venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Recommendations for or against splenectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15480873\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15480888\">",
"      Suspecting the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14834872\">",
"      Disorders that may be confused with HS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14834763\">",
"      Confirming the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14834937\">",
"      Management of anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14834944\">",
"      Consideration of splenectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7079\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7079|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/48/12047\" title=\"figure 1\">",
"      Osmotic fragility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7079|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/1/27670\" title=\"picture 1\">",
"      Spherocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7079|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/50/1836\" title=\"table 1\">",
"      RBC changes HS splenectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9895?source=related_link\">",
"      Clinical features and management of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/46/43753?source=related_link\">",
"      Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/34/6697?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to systemic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=related_link\">",
"      Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=related_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=related_link\">",
"      Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15623?source=related_link\">",
"      Hereditary elliptocytosis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8841?source=related_link\">",
"      Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18808?source=related_link\">",
"      Indications for red blood cell transfusion in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/45/35543?source=related_link\">",
"      Mean corpuscular volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=related_link\">",
"      Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17046?source=related_link\">",
"      Red blood cell mechanics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13352?source=related_link\">",
"      Red blood cell membrane dynamics and organization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9305?source=related_link\">",
"      Spiculated cells (echinocytes and acanthocytes) and target cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=related_link\">",
"      Stomatocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_1_20507="Firearm safety tips";
var content_f20_1_20507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Firearm safety tips",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Any gun is a potential danger to children in the home; the risks must be seriously considered.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Firearms should be stored unloaded, locked up, and out of children's reach.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ammunition should be stored in a separate, locked location.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Quality gun locks, lock boxes, or gun safes should be used on every firearm. When correctly installed, gun locks prevent firearms from being discharged unless the lock is removed.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gun storage keys and lock combinations should be kept hidden in a location separate from the guns.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parents who have guns should take a course in using, maintaining, and storing them safely.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parents should talk to their children about the dangers of guns and teach their children never to touch or play with a gun.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Children should be taught to tell an adult if they find a gun, or, if no adult is present, to call 911 or the local emergency number.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Check with neighbors, friends, relatives, and adults in other homes where the child visits to make sure that if they have firearms in the home, they follow safe storage practices.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: The National Safe Kids Campaign. Firearms: Protecting your family. Available at: www.usa.safekids.org/tier3_cd.cfm?content_item_id=315&amp;folder_id=172 (Accessed on April 28, 2008).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_1_20507=[""].join("\n");
var outline_f20_1_20507=null;
var title_f20_1_20508="Classification of tics";
var content_f20_1_20508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of tics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physiologic tics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mannerisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pathologic tics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Primary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Sporadic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Transient motor or phonic tics (&lt;1 year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Chronic motor or phonic tics (&gt;1 year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Adult-onset (recurrent) tics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Tourette's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Inherited",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Tourette's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Huntington's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Primary dystonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Neuroacanthocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Secondary (\"Tourettism\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Infections: Encephalitis, Creutzfeldt-Jakob disease, Sydenham chorea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drugs: Stimulants, levodopa, carbamazepine, phenytoin, phenobarbital, antipsychotics (tardive tics)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxins: Carbon monoxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Developmental: Static encephalopathy, mental retardation syndromes, chromosomal abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other: Head trauma, stroke, neurocutaneous syndromes, chromosomal abnormalities, schizophrenia, neuroacanthocytosis degenerative disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Related disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stereotypies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Self-injurious behaviors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperactivity syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Compulsions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excessive startle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jumping Frenchman, Latah, Myriachit",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Jankovic, J. Differential diagnosis and etiology of tics. In: Cohen, D, Jankovic, J, Goetz, C, (Eds), Tourette Syndrome, Adv Neurol, Vol. 85, Lippincott Williams and Wilkins, Philadelphia, 2001. p. 15.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_1_20508=[""].join("\n");
var outline_f20_1_20508=null;
var title_f20_1_20509="Quinolone MICs versus GNR I";
var content_f20_1_20509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Activity of quinolones against selected gram-negative and other pathogens in vitro-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Organism",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"6\">",
"       Representative MIC",
"       <sub>",
"        90",
"       </sub>",
"       (range), mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Ciprofloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Norfloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Ofloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Levofloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Moxifloxacin",
"      </td>",
"      <td class=\"subtitle2\">",
"       Gemifloxacin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acinetobacter spp",
"      </td>",
"      <td>",
"       <p>",
"        0.25-2",
"       </p>",
"       <p>",
"        (0.25-&gt;128)",
"       </p>",
"      </td>",
"      <td>",
"       (8-64)",
"      </td>",
"      <td>",
"       <p>",
"        0.25-1",
"       </p>",
"       <p>",
"        (0.25-128)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.4-16",
"       </p>",
"       <p>",
"        (0.12-16)",
"       </p>",
"      </td>",
"      <td>",
"       2-8",
"      </td>",
"      <td>",
"       4-32",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Campylobacter jejuni",
"      </td>",
"      <td>",
"       (0.12-0.78)",
"      </td>",
"      <td>",
"       (0.25-2)",
"      </td>",
"      <td>",
"       (0.12-2)",
"      </td>",
"      <td>",
"       0.4",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chlamydia pneumoniae",
"      </td>",
"      <td>",
"       1-2",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0.03-1",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chlamydia trachomatis",
"      </td>",
"      <td>",
"       1-3.1",
"      </td>",
"      <td>",
"       &ge;16",
"      </td>",
"      <td>",
"       0.5- 1.6",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       0.03-0.125",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Citrobacter spp",
"      </td>",
"      <td>",
"       <p>",
"        0.12",
"       </p>",
"       <p>",
"        (0.03-0.78)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.5",
"       </p>",
"       <p>",
"        (0.25-50)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.5",
"       </p>",
"       <p>",
"        (0.1-25)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.12-6.25",
"       </p>",
"       <p>",
"        6.25",
"       </p>",
"      </td>",
"      <td>",
"       0.06-2",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Enterobacter cloacae",
"      </td>",
"      <td>",
"       <p>",
"        0.12",
"       </p>",
"       <p>",
"        (0.03-0.5)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.5",
"       </p>",
"       <p>",
"        (&lt;0.25-2)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.25",
"       </p>",
"       <p>",
"        (0.1-1)",
"       </p>",
"      </td>",
"      <td>",
"       0.12-0.78",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"      <td>",
"       0.25-1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Escherichia coli",
"      </td>",
"      <td>",
"       <p>",
"        0.06",
"       </p>",
"       <p>",
"        (0.01-0.25)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.12",
"       </p>",
"       <p>",
"        (0.01-0.5)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.12",
"       </p>",
"       <p>",
"        (0.02-1)",
"       </p>",
"      </td>",
"      <td>",
"       0.05-0.12",
"      </td>",
"      <td>",
"       0.06-1",
"      </td>",
"      <td>",
"       0.016-0.03",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Haemophilus influenzae",
"      </td>",
"      <td>",
"       (0.008-0.06)",
"      </td>",
"      <td>",
"       0.06",
"      </td>",
"      <td>",
"       (0.06-0.5)",
"      </td>",
"      <td>",
"       0.025-0.06",
"      </td>",
"      <td>",
"       0.03-0.06",
"      </td>",
"      <td>",
"       &le;0.004-0.03",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Klebsiella spp",
"      </td>",
"      <td>",
"       <p>",
"        0.12",
"       </p>",
"       <p>",
"        (0.02-1)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.5",
"       </p>",
"       <p>",
"        (0.2-2)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        0.25",
"       </p>",
"       <p>",
"        (0.12-1)",
"       </p>",
"      </td>",
"      <td>",
"       0.1-3.1",
"      </td>",
"      <td>",
"       0.12-0.25",
"      </td>",
"      <td>",
"       0.25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Legionella spp",
"      </td>",
"      <td>",
"       0.12",
"      </td>",
"      <td>",
"       (0.2-2)",
"      </td>",
"      <td>",
"       0.06",
"      </td>",
"      <td>",
"       (0.03-0.25)",
"      </td>",
"      <td>",
"       0.015",
"      </td>",
"      <td>",
"       0.003-0.006",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MIC",
"     <sub>",
"      90",
"     </sub>",
"     : minimal inhibitory concentration for 90 percent of strains.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Eliopoulos, GM, Eliopoulos, CT. Activity in vitro of the quinolones. In: Quinolone antimicrobial agents (2nd ed), Hooper, DC, Wolfson, JS (Eds), American Society for Microbiology, Washington, DC, 1993, p. 161, and Wolfson, JS, Hooper, DC, Clin Microbiol Rev 1989; 2:378. Perry, CM, Barman Balfour, JA, Lamb, HM. Drugs 1999; 58:683. Barman Balfour, JA, Wiseman, LR. Drugs 1999; 57:363. Blondeau, JM. J Antimicrob Chemother 1999; 43(SupplB):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_1_20509=[""].join("\n");
var outline_f20_1_20509=null;
var title_f20_1_20510="Electrical cardioversion AF";
var content_f20_1_20510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72962%7ECARD%2F58616%7ECARD%2F65532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72962%7ECARD%2F58616%7ECARD%2F65532&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/ESC guideline summary: Direct-current (DC) cardioversion of atrial fibrillation (AF) and flutter (AFl)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that immediate R-wave synchronized DC cardioversion of AF or AFl is indicated in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; AF with a rapid ventricular response that does not respond promptly to pharmacologic measures and there is evidence of ongoing myocardial ischemia, symptomatic hypotension, angina, or heart failure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Pre-excitation in the presence of very rapid tachycardia or hemodynamic instability.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Unacceptable symptoms in the absence of hemodynamic instability. Repeated direct current cardioversion attempts may be made following administration of antiarrhythmic drugs for early relapse. In this category, immediate cardioversion may not be necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of DC cardioversion of AF or AFl for patients in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Part of a long-term management strategy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; If the patient prefers, management of symptomatic or recurrent AF if used infrequently.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that DC cardioversion of AF or AFl is not useful or may be harmful to patients in the following settings and should therefore be avoided",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Frequent repetition of direct current cardioversion for repeated relapses of AF after short periods of sinus rhythm in patients who have received procedures despite prophylactic antiarrhythmic drug treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Digitalis toxicity or hypokalemia, settings in which DC cardioversion is contraindicated.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006; 48:e149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/ESC guideline summary: Pharmacologic cardioversion of atrial fibrillation (AF)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following drugs are effective for cardioversion of AF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Flecainide.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Dofetilide.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Propafenone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Ibutilide.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence",
"or opinion is in favor of the usefulness of the following drugs for",
"cardioversion of AF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Amiodarone, including use as an out-patient when rapid restoration of sinus rhythm does not appear to be necessary.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; A single oral bolus (\"pill-in-the-pocket\") of propafenone or flecainide in the out-patient setting in selected patients in whom the safety and efficacy of this approach has been demonstrated in hospital and who meet the following criteria:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. The absence of sinus and atrioventricular (AV) node dysfunction, bundle branch block, QT interval prolongation, Brugada syndrome, and structural heart disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. The presence of AV nodal blockade with a beta blocker or nondihydropyridine calcium channel blocker to prevent rapid AV conduction if atrial flutter occurs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence",
"or opinion is less well established for the usefulness of the following",
"drugs for cardioversion of AF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Quinidine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Procainamide.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or",
"general agreement that the following drugs for cardioversion of AF are",
"not useful or may be harmful",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Digoxin.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Sotalol.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; For out-of-hospital cardioversion, quinidine, procainamide, disopyramide, and dofetilide.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). J Am Coll Cardiol 2006; 48:e149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA/ESC guideline summary: Recommended doses of drugs (listed alphabetically) proven effective for pharmacological cardioversion of atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Route of administration",
"      </td>",
"      <td class=\"subtitle1\">",
"       Dosage&Delta;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Potential adverse effects",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Amiodarone",
"      </td>",
"      <td>",
"       Oral",
"      </td>",
"      <td>",
"       <p>",
"        Inpatient: 1.2 to 1.8 g per day in divided dose until 10 g total, then 200 to 400 mg per day as single dose",
"       </p>",
"       <p>",
"        Outpatient 600 to 800 mg/day divided dose until 10 g total, then 200 to 400 mg per day maintenance",
"       </p>",
"      </td>",
"      <td rowspan=\"2\">",
"       Hypotension, bradycardia, QT prolongation, torsade de pointes (rare), GI upset, constipation, phlebitis (IV use)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intravenous (IV)/oral",
"      </td>",
"      <td>",
"       5 to 7 mg/kg over 30 to 60 min, then 1.2 to 1.8 g per day continuous IV or in divided oral doses until 10 g total, then 200 to 400 mg per day maintenance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dofetilide",
"      </td>",
"      <td>",
"       Oral",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         Creatinine clearance (mL/min):",
"        </strong>",
"       </p>",
"       <p>",
"        Greater than 60: 500 mcg BID",
"       </p>",
"       <p>",
"        40 to 60: 250 mcg BID",
"       </p>",
"       <p>",
"        20 to 40: 125 mcg BID",
"       </p>",
"       <p>",
"        Less than 20: Contraindicated",
"       </p>",
"      </td>",
"      <td>",
"       QT prolongation, torsade de pointes; adjust dose for renal function, body size, and age",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Flecainide",
"      </td>",
"      <td>",
"       Oral",
"      </td>",
"      <td>",
"       200 to 300 mg&bull;",
"      </td>",
"      <td rowspan=\"2\">",
"       Hypotension, rapidly conducting atrial flutter",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intravenous",
"      </td>",
"      <td>",
"       1.5 to 3.0 m per kg over 10 to 20 min&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ibutilide",
"      </td>",
"      <td>",
"       Intravenous",
"      </td>",
"      <td>",
"       1 mg over 10 min; repeat 1 mg when necessary",
"      </td>",
"      <td>",
"       QT prolongation, torsade de pointes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Propafenone",
"      </td>",
"      <td>",
"       Oral",
"      </td>",
"      <td>",
"       450 to 600 mg",
"      </td>",
"      <td rowspan=\"2\">",
"       Hypotension, rapidly conducting atrial flutter",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intravenous",
"      </td>",
"      <td>",
"       1.5 to 2.0 mg per kg over 10 to 20 min&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Quinidine&loz;",
"      </td>",
"      <td>",
"       Oral",
"      </td>",
"      <td>",
"       0.75 to 1.5 g in divided doses over 6 to 12 h, usually with a rate-slowing drug",
"      </td>",
"      <td>",
"       QT prolongation, torsade de pointes, gastrointestinal upset, hypotension",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     &Delta; Dosages given in the table may differ from those recommended by the manufacturers.",
"     <br>",
"      &bull; Insufficient data are available on which to base specific recommendations for the use of one loading regimen over another for patients with ischemic heart disease or impaired left ventricular function, and these drugs should be used cautiously or not at all in such patients.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol 2006; 48:e149.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_1_20510=[""].join("\n");
var outline_f20_1_20510=null;
var title_f20_1_20511="Displaced transverse distal phalanx shaft fracture";
var content_f20_1_20511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Displaced transverse distal phalanx shaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 196px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A transverse fracture that passes between the terminal insertions of the extensor and flexor tendons is an unstable fracture pattern due to the opposing deforming forces and usually has an apex dorsal angulation due to the greater pull of the flexor tendon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_1_20511=[""].join("\n");
var outline_f20_1_20511=null;
